

# THE INTERNATIONAL CML FOUNDATION

England & Wales · Charity number 1132984

## Details

---

**Status** Registered

**Legal form** Charitable company

**Company number** [06996068](#)

**Registered** 2009-11-26

**Register** [View on the Charity Commission register](#)

## Contact

---

**Address** C/O Gibbons Mannington & Phipps Lp  
20-22 Eversley Road  
Bexhill-On-Sea  
East Sussex  
TN40 1HE

**Phone** 01424210530

**Email** [info@cml-foundation.org](mailto:info@cml-foundation.org)

**Website** [www.cml-foundation.org](http://www.cml-foundation.org)

## Activities

---

**Objects:** 3.1. THE GENERAL CHARITABLE OBJECTS FOR WHICH THE FOUNDATION IS ESTABLISHED ARE THE ADVANCEMENT OF HEALTH BY THE IMPROVEMENT OF THE TREATMENT IN ALL PARTS OF THE WORLD OF CHRONIC MYELOID LEUKAEMIA AND RELATED DISEASES (TOGETHER "CML") AND FOR THE PURPOSE OF CARRYING OUT THOSE GENERAL OBJECTS THE PRIMARY OBJECTS OF THE FOUNDATION ARE IN PARTICULAR:- 3.1.1. TO IMPROVE CLINICAL PRACTICE AND DISEASE MONITORING IN THE TREATMENT OF CML3.1.2. TO SUPPORT ENCOURAGE AND PROMOTE RESEARCH INTO THE CAUSES, PREVENTION, STUDYAND TREATMENT OF CML3.1.3. TO PROMOTE AND SUPPORT THE EDUCATION OF AND DISSEMINATE KNOWLEDGE AMONGSTCLINICIANS, SCIENTISTS, HEALTH PROFESSIONALS AND PATIENTS IN MATTERS CONCERNINGCML3.1.4. TO PROMOTE, FOSTER AND CO-ORDINATE COLLABORATION THAT IS PARTICULARLY (BUT NOTEXCLUSIVELY) INTERNATIONAL AND IS NOT ONLY IN THE AREAS AND ACTIVITIES OF CLINICALPRACTICE DISEASE MONITORING AND RESEARCH INTO CML BUT ALSO IN ANY AREA ORACTIVITY WHICH IS OR MAY BE CONDUCIVE TO THE ACCELERATION OF THE CONTROL AND/ORCURE OF CML3.1.5. TO PROMOTE SET UP ESTABLISH AND SUPPORT AND SHARE AND EXCHANGE KNOWLEDGE WITH OTHER ORGANISATIONS WHOSE OBJECTS ARE SIMILAR TO THESE GENERAL OR PRIMARY OBJECTS3.1.6. TO ASSIST OR PROMOTE ANY OTHER CHARITABLE PURPOSES WHICH ARE RELATED TO THESEGENERAL AND PRIMARY OBJECTS

**Activities:** The advancement of health by the improvement of the treatment in all parts of the world of chronic myeloid leukaemia and related diseases.

## **Classification**

---

- **How:** Provides Services, Provides Advocacy/advice/information, Sponsors Or Undertakes Research
- **What:** Education/training, The Advancement Of Health Or Saving Of Lives
- **Who:** The General Public/mankind

## Geography

---

- **Area of benefit:** THE WORLD
- Armenia
- Australia
- Belarus
- Botswana
- Brazil
- China
- Ethiopia
- Georgia
- Ghana
- India
- Indonesia
- Kenya
- Kyrgyzstan
- Macedonia
- Nepal
- Niger
- Nigeria
- Pakistan
- Papua New Guinea
- Paraguay
- Philippines
- Senegal
- Togo
- Ukraine
- United States
- Uruguay
- Throughout England And Wales

## Finances

Period end	Income	Expenditure	Assets	Employees
2024-08-31	£319,194	£247,722	-	-
2023-08-31	£107,363	£243,847	-	-
2022-08-31	£209,231	£186,038	-	-
2021-08-31	£69,203	£146,660	-	-
2020-08-31	£200,371	£227,287	-	-

## Trustees

Name	Role	Appointed
<b>Dr TIMOTHY PETER HUGHES</b>	Chair	
Dr ANDREAS HOCHHAUS		2012-03-16
Dr BRIAN DRUKER		2012-03-16
Dr Charles Schiffer		2013-06-26
Dr EDUARDO CORTES		2012-03-16
Dr JERALD RADICH		2012-03-16
Giuseppe Saglio		2018-03-01
Michael Mauro		2018-03-01
PROFESSOR JANE FELICITY APPERLEY		2014-03-19

**THE INTERNATIONAL CML FOUNDATION**

England & Wales - Charity number 1132984

---

# Accounts

---

**REGISTERED COMPANY NUMBER: 06996068 (England and Wales)**  
**REGISTERED CHARITY NUMBER: 1132984**

**REPORT OF THE TRUSTEES AND  
UNAUDITED FINANCIAL STATEMENTS  
FOR THE YEAR ENDED 31ST AUGUST 2024  
FOR  
THE INTERNATIONAL CML FOUNDATION**

Gibbons Mannington & Phipps LLP  
Chartered Accountants  
20 Eversley Road  
Bexhill-on-Sea  
East Sussex  
TN40 1HE

**THE INTERNATIONAL CML FOUNDATION**

**CONTENTS OF THE FINANCIAL STATEMENTS  
FOR THE YEAR ENDED 31ST AUGUST 2024**

---

	<b>Page</b>
<b>Report of the Trustees</b>	1 to 4
<b>Independent Examiner's Report</b>	5
<b>Statement of Financial Activities</b>	6
<b>Balance Sheet</b>	7
<b>Notes to the Financial Statements</b>	8 to 14

---

**REPORT OF THE TRUSTEES  
FOR THE YEAR ENDED 31ST AUGUST 2024**

---

The trustees who are also directors of the charity for the purposes of the Companies Act 2006, present their report with the financial statements of the charity for the year ended 31st August 2024. The trustees have adopted the provisions of Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2019).

**OBJECTIVES AND ACTIVITIES**

**Objectives and aims**

The object of the Foundation is the advancement of health by the improvement of the treatment in all parts of the world of chronic myeloid leukaemia and related diseases (together "CML") and for the purpose of carrying out those general objects, the primary objects of the Foundation are in particular:-

- (i) to improve clinical practice and disease monitoring in the treatment of CML
- (ii) to support, encourage and promote research into the causes, prevention, study and treatment of CML
- (iii) to promote and support the education of and disseminate knowledge amongst clinicians, scientists, health professionals and patients in matters concerning CML
- (iv) to promote, foster and co-ordinate collaboration that is particularly (but not exclusively) international and is not only in the areas and activities of clinical practice disease monitoring and research into CML but also in any area or activity which is or may be conducive to the acceleration of the control and/or cure of CML
- (v) to promote, set up, establish and support and share and exchange knowledge with other organisations whose objects are similar to these general or primary objects
- (vi) to assist or promote any other charitable purposes which are related to these general and primary objects.

**Significant activities**

In furtherance of the objects, the Foundation has the following powers:-

- (i) to promote or carry out research
- (ii) to provide advice
- (iii) to give and exchange information and advice and promote learning, study and research
- (iv) to commission, publish, distribute and contribute to papers, books, periodicals, reports, leaflets, posters and other publications of any description
- (v) to hold, attend and sponsor conferences, meetings, lectures, exhibitions and discussions
- (vi) to raise funds and to apply for and solicit grants from pharmaceutical companies anywhere in the world.

**Public benefit**

The Trustees have considered their duty to have due regard to public benefit guidance published by the Commission and in their opinion, the foregoing report on the achievements and performance demonstrates that they have complied therewith.

**REPORT OF THE TRUSTEES  
FOR THE YEAR ENDED 31ST AUGUST 2024**

---

**ACHIEVEMENT AND PERFORMANCE**

**Charitable activities**

The International CML Foundation (iCMLf) is a global charity working to improve the outcomes for people with chronic myeloid leukemia (CML), particularly in low- and middle-income countries (LMICs). Our mission is to foster global collaboration, share best practices, build clinical capacity, and accelerate research to ultimately find a cure for CML.

In 2023-2024, the iCMLf continued to address unmet needs in CML care and education by driving global research, enhancing medical education, and fostering access to expert guidance and clinical excellence.

**SUMMARY OF CORE PROGRAMS AND IMPACT**

**1. Global Research**

The iCMLf leads international collaborations that investigate critical questions to improve CML treatment, including:

- **Big Data Projects:** Through the Genomics Alliance and TFR (Treatment-Free Remission) Alliance, the Foundation is working to analyse over 3,400 datasets from 27 sites across 19 countries. These projects aim to understand genomic drivers of CML and improve the success rates of therapy discontinuation strategies.
- **Research Publications:** Three significant peer-reviewed studies were published this year, providing new insights into CML biology and management.

**2. Education and Clinical Capacity Building**

Physician education on clinical management and diagnostics remains a core focus for the iCMLf. Programs include:

- **Knowledge Centre:** Over 1,200 professionals accessed expert-led educational modules, including a new focus on fertility and pregnancy in CML.
- **Regional Discussion Groups:** Nine sessions held across three continents engaged 250 physicians from 44 countries, promoting region-specific dialogue and clinical learning.
- **Clinical Conversations and Forums:** These sessions facilitated global peer learning. Over 2,000 on-demand views were recorded across three key sessions.
- **Publications and Case discussions:** More than 8,000 views of challenging case discussions, including complex cases on pediatric relapse, pregnancy, and fourth-line therapies, provided practical guidance for clinicians.
- **In-Person Events:** iCMLf convened expert panels at major global events such as the John Goldman Conference, the American Society of Hematology meeting, and the Indian Cancer Congress.

**3. Awareness, Recognition, and Advocacy**

- **iCMLf Prizes:** Prestigious awards were presented to leaders in research, clinical practice, and patient advocacy.
- **Patient Support:** Programs and community engagements such as Friends of Max in India amplified patient voices and needs.

**FINANCIAL REVIEW**

**Financial position**

The financial position of the International CML Foundation remains solid.

**Expenditure**

- Total expenditure on programs: 67% on physician education, 11% on disease research, and 9% on patient support.
- 36% of all expenditures directly supported people with CML in LMICs.
- 13% was allocated to fundraising and 10% to governance.

**Principal funding sources**

The iCMLf works closely with industry and community partners to secure unrestricted grants and sponsorship for our programs and activities. The iCMLf requests donations through the iCMLf website.

**REPORT OF THE TRUSTEES  
FOR THE YEAR ENDED 31ST AUGUST 2024**

---

**FINANCIAL REVIEW**

**Reserves policy**

The reserves at the year end were £263,528 (2023 - £192,056). It is the policy of the Trustees to maintain sufficient reserves to ensure the day to day running of the Foundation. The level of reserves and current financial commitments are reviewed regularly at Trustees' meetings. The Foundation plans to hold a minimum of £150,000 as reserve funding. This is the amount for the foundation to operate without further income/outgoings for one year.

**FUTURE PLANS**

The Trustees are proud of the iCMLf's achievements in 2023-2024. Our commitment to equity in CML care, global collaboration, and scientific innovation continues to drive tangible improvements in patient outcomes. Looking ahead, the iCMLf will build on the momentum of its current programs by expanding its research networks, launching new regionally focused education initiatives, and deepening engagement with patient communities. The Foundation remains focused on supporting clinicians and researchers worldwide as we work toward a cure for CML.

**STRUCTURE, GOVERNANCE AND MANAGEMENT**

**Governing document**

The charity is controlled by its governing document, a deed of trust, and constitutes a limited company, limited by guarantee, as defined by the Companies Act 2006.

**Recruitment and appointment of new trustees**

The power of appointing new or additional Trustees is vested in the existing Trustees. Prior to appointment, new Trustees would be introduced to the workings of the Foundation and advised of their responsibilities.

The iCMLf Board of Directors is composed of globally renowned hematologists and researchers who provide strategic leadership to the Foundation. To ensure diverse perspectives, the Board includes representatives from low- and middle-income countries, notably Brazil and India. In 2024, the iCMLf established a Patient Advisory Committee to strengthen patient representation within its work. This new committee brings together eight CML patients and advocates from five countries, who will collaborate with the Scientific Advisory Committee to help shape and support the Foundation's mission. The iCMLf's operations are managed by a multidisciplinary team based across Australia, the United Kingdom, Germany, the United States, and India.

**Organisational structure**

The Chief Executive reports to the eleven iCMLf Directors, specifically the iCMLf Chairman. The iCMLf Directors are supported by an Executive Committee of 3 directors and the Chief Executive.

The operational team; Communications Director, Communications Manager, Digital Media Officer, and Program Manager, report to the Chief Executive. In June 2024 a Development Manager was hired to join the operational team.

Strategic direction, financial review and budget approval are set at an annual iCMLf Directors meeting in September/October each year. Further planning and discussion meetings are held quarterly.

Strategic planning is assisted with an annual advisor's meeting. This includes the Scientific Advisory Committee and Patient Advisory Committee. The Patient Advisors also meet quarterly.

The operational team meets quarterly. The Communications Director/Communications Manager meet biweekly with the Chief Executive respectively. The Program Manager and Development Manager meet weekly with the Chief Executive for business planning. The Chief Executive and iCMLf Chairman meet monthly.

Decisions are escalated from the operational team to the Chief Executive, iCMLf Chairman, iCMLf Executive Committee and iCMLf Board of Directors according to scale and impact.

**REFERENCE AND ADMINISTRATIVE DETAILS**

**Registered Company number**

06996068 (England and Wales)

**REPORT OF THE TRUSTEES  
FOR THE YEAR ENDED 31ST AUGUST 2024**

---

**Registered Charity number**

1132984

**Registered office**

20 Eversley Road  
Bexhill-on-Sea  
East Sussex  
TN40 1HE

**Trustees**

Professor T P Hughes  
Professor J Cortes Professor  
Professor B Druker Professor  
Professor A Hochhaus Professor  
Professor J Radich Professor  
Professor C Schiffer Professor  
Professor J F Apperley DM FRCP/Path Professor  
Professor M Mauro Professor  
Professor G Saglio Professor  
Dr K B B Pagnano Medical doctor (appointed 1/10/2023)  
Dr H Malhotra Medical doctor (appointed 1/10/2023)

**Company Secretary**

Ms N C Evans

**Independent Examiner**

R Appleyard FCA  
Gibbons Mannington & Phipps LLP  
Chartered Accountants  
20 Eversley Road  
Bexhill-on-Sea  
East Sussex  
TN40 1HE

**Bankers**

HSBC Bank, 152 Portobello Road, London, W11 2EA

**QUALIFYING THIRD PARTY INDEMNITY PROVISION**

There is a qualifying third party indemnity in force at the date of approval of this report, for the benefit of every director or other officer or auditor.

This report has been prepared in accordance with the special provisions of Part 15 of the Companies Act 2006 relating to small companies.

30/05/2025

Approved by order of the board of trustees on ..... and signed on its behalf by:

.....  
Professor J Cortes - Trustee

**INDEPENDENT EXAMINER'S REPORT TO THE TRUSTEES OF  
THE INTERNATIONAL CML FOUNDATION (REGISTERED NUMBER: 06996068)**

---

**Independent examiner's report to the trustees of The International CML Foundation ('the Company')**

I report to the charity trustees on my examination of the accounts of the Company for the year ended 31st August 2024.

**Responsibilities and basis of report**

As the charity's trustees of the Company (and also its directors for the purposes of company law) you are responsible for the preparation of the accounts in accordance with the requirements of the Companies Act 2006 ('the 2006 Act').

Having satisfied myself that the accounts of the Company are not required to be audited under Part 16 of the 2006 Act and are eligible for independent examination, I report in respect of my examination of your charity's accounts as carried out under Section 145 of the Charities Act 2011 ('the 2011 Act'). In carrying out my examination I have followed the Directions given by the Charity Commission under Section 145(5) (b) of the 2011 Act.

**Independent examiner's statement**

Since your charity's gross income exceeded £250,000 your examiner must be a member of a listed body. I can confirm that I am qualified to undertake the examination because I am a member of the Institute of Chartered Accountants in England and Wales, which is one of the listed bodies.

I have completed my examination. I confirm that no matters have come to my attention in connection with the examination giving me cause to believe:

1. accounting records were not kept in respect of the Company as required by Section 386 of the 2006 Act; or
2. the accounts do not accord with those records; or
3. the accounts do not comply with the accounting requirements of Section 396 of the 2006 Act other than any requirement that the accounts give a true and fair view which is not a matter considered as part of an independent examination; or
4. the accounts have not been prepared in accordance with the methods and principles of the Statement of Recommended Practice for accounting and reporting by charities (applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102)).

I have no concerns and have come across no other matters in connection with the examination to which attention should be drawn in this report in order to enable a proper understanding of the accounts to be reached.

R Appleyard FCA  
The Institute of Chartered Accountants in England and Wales

Gibbons Mannington & Phipps LLP  
Chartered Accountants  
20 Eversley Road  
Bexhill-on-Sea  
East Sussex  
TN40 1HE

Date: ....30 May 2025.....

**THE INTERNATIONAL CML FOUNDATION**

**STATEMENT OF FINANCIAL ACTIVITIES  
FOR THE YEAR ENDED 31ST AUGUST 2024**

	Notes	Unrestricted funds £	Restricted funds £	<b>2024 Total funds £</b>	2023 Total funds £
<b>INCOME AND ENDOWMENTS FROM</b>					
Donations and legacies		<b>104,927</b>	<b>214,267</b>	<b>319,194</b>	107,364
Other income	2	<b>(8,700)</b>	-	<b>(8,700)</b>	(17,489)
<b>Total</b>		<b>96,227</b>	<b>214,267</b>	<b>310,494</b>	89,875
<b>EXPENDITURE ON</b>					
<b>Charitable activities</b>					
Preceptorships		<b>3,808</b>	-	<b>3,808</b>	-
Diagnostics program		-	<b>11,841</b>	<b>11,841</b>	5,328
Scientific meetings		<b>31,833</b>	-	<b>31,833</b>	43,734
Clinical and Scientific communication		<b>35,060</b>	<b>31,097</b>	<b>66,157</b>	17,799
Fundraising		<b>25,784</b>	-	<b>25,784</b>	21,949
Cure Consortium		-	<b>1,820</b>	<b>1,820</b>	-
Covid-19 & CML Study		<b>1,750</b>	-	<b>1,750</b>	2,722
Knowledge Centre		<b>3,675</b>	-	<b>3,675</b>	46,023
Clinical Conversations program		<b>11,585</b>	-	<b>11,585</b>	9,175
Research		-	-	-	3,552
RDG		<b>17,160</b>	<b>15,549</b>	<b>32,709</b>	18,630
Alliances		-	<b>11,103</b>	<b>11,103</b>	13,608
Education meetings		<b>1,554</b>	<b>20,405</b>	<b>21,959</b>	-
Other		<b>14,998</b>	-	<b>14,998</b>	43,839
<b>Total</b>		<b>147,207</b>	<b>91,815</b>	<b>239,022</b>	226,359
<b>NET INCOME/(EXPENDITURE)</b>		<b>(50,980)</b>	<b>122,452</b>	<b>71,472</b>	(136,484)
<b>RECONCILIATION OF FUNDS</b>					
Total funds brought forward		<b>81,912</b>	<b>110,144</b>	<b>192,056</b>	328,540
<b>TOTAL FUNDS CARRIED FORWARD</b>		<b>30,932</b>	<b>232,596</b>	<b>263,528</b>	192,056

The notes form part of these financial statements

**THE INTERNATIONAL CML FOUNDATION (REGISTERED NUMBER: 06996068)**

**BALANCE SHEET  
31ST AUGUST 2024**

	Notes	Unrestricted funds £	Restricted funds £	2024 Total funds £	2023 Total funds £
<b>CURRENT ASSETS</b>					
Debtors	9	<b>36,315</b>	<b>15,317</b>	<b>51,632</b>	113,534
Cash at bank and in hand		<b>1,398</b>	<b>217,278</b>	<b>218,676</b>	85,374
		<b>37,713</b>	<b>232,595</b>	<b>270,308</b>	198,908
<b>CREDITORS</b>					
Amounts falling due within one year	10	<b>(6,780)</b>	-	<b>(6,780)</b>	(6,852)
<b>NET CURRENT ASSETS</b>		<b>30,933</b>	<b>232,595</b>	<b>263,528</b>	192,056
<b>TOTAL ASSETS LESS CURRENT LIABILITIES</b>		<b>30,933</b>	<b>232,595</b>	<b>263,528</b>	192,056
<b>NET ASSETS</b>		<b>30,933</b>	<b>232,595</b>	<b>263,528</b>	192,056
<b>FUNDS</b>					
Unrestricted funds	11			<b>30,933</b>	81,912
Restricted funds				<b>232,595</b>	110,144
<b>TOTAL FUNDS</b>				<b>263,528</b>	192,056

The charitable company is entitled to exemption from audit under Section 477 of the Companies Act 2006 for the year ended 31st August 2024.

The members have not required the company to obtain an audit of its financial statements for the year ended 31st August 2024 in accordance with Section 476 of the Companies Act 2006.

The trustees acknowledge their responsibilities for

- ensuring that the charitable company keeps accounting records that comply with Sections 386 and 387 of the Companies Act 2006 and
- preparing financial statements which give a true and fair view of the state of affairs of the charitable company as at the end of each financial year and of its surplus or deficit for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the charitable company.

These financial statements have been prepared in accordance with the provisions applicable to charitable companies subject to the small companies regime.

The financial statements were approved by the Board of Trustees and authorised for issue on ...30/05/2025..... and were signed on its behalf by:



.....  
J Cortes - Trustee

## 1. ACCOUNTING POLICIES

### **Basis of preparing the financial statements**

The financial statements of the charitable company, which is a public benefit entity under FRS 102, have been prepared in accordance with the Charities SORP (FRS 102) 'Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2019)', Financial Reporting Standard 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland' and the Companies Act 2006. The financial statements have been prepared under the historical cost convention.

### **Income**

Items of income are recognised and included in the accounts when all of the following criteria are met:

- The charity or its subsidiary have entitlement to the funds;
- any performance conditions attached to the item(s) of income have been met or are fully within the control of the charity or its subsidiary;
- there is sufficient certainty that receipt of the income is considered probable; and
- the amount can be measured reliably.

### **Expenditure**

Liabilities are recognised as expenditure as soon as there is a legal or constructive obligation committing the charity to that expenditure, it is probable that a transfer of economic benefits will be required in settlement and the amount of the obligation can be measured reliably. Expenditure is accounted for on an accruals basis and has been classified under headings that aggregate all cost related to the category. Where costs cannot be directly attributed to particular headings they have been allocated to activities on a basis consistent with the use of resources.

### **Debtors**

Debtors are recognised at the settlement amount due after any trade discount offered. Prepayments are valued at the amount prepaid after taking account of any trade discounts due.

### **Creditors and provisions**

Creditors and provisions are recognised where the charity has a present obligation resulting from a past event that will probably result in the transfer of funds to a third party and the amount due to settle the obligation can be measured or estimated reliably. Creditors and provisions are normally recognised at their settlement amount after allowing for any trade discounts due.

### **Taxation**

The charity is exempt from corporation tax on its charitable activities.

### **Fund accounting**

Unrestricted funds can be used in accordance with the charitable objectives at the discretion of the trustees.

Restricted funds can only be used for particular restricted purposes within the objects of the charity. Restrictions arise when specified by the donor or when funds are raised for particular restricted purposes.

Further explanation of the nature and purpose of each fund is included in the notes to the financial statements.

### **Foreign currencies**

Assets and liabilities in foreign currencies are translated into sterling at the rates of exchange ruling at the balance sheet date. Transactions in foreign currencies are translated into sterling at the rate of exchange ruling at the date of transaction. Exchange differences are taken into account in arriving at the operating result and are shown as other income.

**THE INTERNATIONAL CML FOUNDATION**

**NOTES TO THE FINANCIAL STATEMENTS - continued  
FOR THE YEAR ENDED 31ST AUGUST 2024**

**2. OTHER INCOME**

Other income consists of the profit/loss on foreign currency exchange in accordance with the accounting policy on foreign exchange transactions.

**3. SUPPORT COSTS**

	Management fees £	Finance £	Other £	Governance costs £	Totals £
Other resources expended	<b>8,710</b>	<b>363</b>	<b>1,329</b>	<b>4,596</b>	<b>14,998</b>
Preceptorships	-	<b>17</b>	-	-	<b>17</b>
Diagnostics program	<b>11,841</b>	-	-	-	<b>11,841</b>
Scientific meetings	<b>30,221</b>	-	-	-	<b>30,221</b>
Clinical and Scientific communication	<b>58,490</b>	-	-	-	<b>58,490</b>
Fundraising	<b>21,983</b>	<b>147</b>	<b>1,944</b>	-	<b>24,074</b>
Cure Consortium	<b>1,820</b>	-	-	-	<b>1,820</b>
Covid-19 & CML Study	<b>1,750</b>	-	-	-	<b>1,750</b>
Knowledge Centre	<b>3,675</b>	-	-	-	<b>3,675</b>
Clinical Conversations program	<b>11,585</b>	-	-	-	<b>11,585</b>
RDG	<b>31,124</b>	<b>18</b>	-	-	<b>31,142</b>
Alliances	<b>11,103</b>	-	-	-	<b>11,103</b>
	<b>192,302</b>	<b>545</b>	<b>3,273</b>	<b>4,596</b>	<b>200,716</b>

Support costs, included in the above, are as follows:

**Management fees**

	Other resources expended £	Diagnostics program £	Scientific meetings £	Clinical and Scientific communication £
Management & admin	<b>8,710</b>	<b>11,841</b>	<b>30,221</b>	<b>58,490</b>
	Fundraising £	Cure Consortium £	Covid-19 & CML Study £	Knowledge Centre £
Management & admin	<b>21,983</b>	<b>1,820</b>	<b>1,750</b>	<b>3,675</b>
	Clinical Conversations program £	RDG £	Alliances £	Total activities £
Management & admin	<b>11,585</b>	<b>31,124</b>	<b>11,103</b>	<b>170,093</b>

**2024**

2023

**THE INTERNATIONAL CML FOUNDATION**

**NOTES TO THE FINANCIAL STATEMENTS - continued  
FOR THE YEAR ENDED 31ST AUGUST 2024**

**3. SUPPORT COSTS - continued  
Finance**

	Other resources expended £	Preceptorships £	Fundraising £
Bank charges	<u>363</u>	<u>17</u>	<u>147</u>
		<b>2024</b>	2023
		Total activities £	Total activities £
Bank charges	<u>18</u>	<u>545</u>	<u>507</u>
<b>Other</b>		<b>2024</b>	2023
	Other resources expended £	Fundraising £	Total activities £
Sundry office costs	<u>1,329</u>	<u>1,944</u>	<u>3,273</u>
		<b>2024</b>	2023
<b>Governance costs</b>		Other resources expended £	Total activities £
Accountancy - Independent examination fee		<u>4,596</u>	<u>4,584</u>

**4. NET INCOME/(EXPENDITURE)**

Net income/(expenditure) is stated after charging/(crediting):

	2024 £	2023 £
Accountancy - Independent examination fee	<u>4,596</u>	<u>4,584</u>

**5. TRUSTEES' REMUNERATION AND BENEFITS**

There were no trustees' remuneration or other benefits for the year ended 31st August 2024 nor for the year ended 31st August 2023.

**Trustees' expenses**

There were no trustees' expenses paid for the year ended 31st August 2024 nor for the year ended 31st August 2023.

**THE INTERNATIONAL CML FOUNDATION**

**NOTES TO THE FINANCIAL STATEMENTS - continued  
FOR THE YEAR ENDED 31ST AUGUST 2024**

**6. STAFF COSTS**

The average monthly number of employees during the year was as follows:

Charitable activities	<b>2024</b> <b>6</b>	2023 5
	<u>        </u>	<u>        </u>

The number of employees whose employee benefits (excluding employer pension costs) exceeded £60,000 was:

£80,001 - £90,000	<b>2024</b> <b>1</b>	2023 -
£90,001 - £100,000	-	1
	<u>        </u>	<u>        </u>
	<b>1</b>	1
	<u>        </u>	<u>        </u>

**7. COMPARATIVES FOR THE STATEMENT OF FINANCIAL ACTIVITIES**

	Unrestricted funds £	Restricted funds £	Total funds £
<b>INCOME AND ENDOWMENTS FROM</b>			
Donations and legacies	82,599	24,765	107,364
Other income	(17,489)	-	(17,489)
<b>Total</b>	<u>65,110</u>	<u>24,765</u>	<u>89,875</u>
<b>EXPENDITURE ON</b>			
<b>Charitable activities</b>			
Diagnostics program	-	5,328	5,328
Scientific meetings	43,734	-	43,734
Clinical and Scientific communication	13,696	4,103	17,799
Fundraising	21,949	-	21,949
Covid-19 & CML Study	2,722	-	2,722
Knowledge Centre	41,118	4,905	46,023
Clinical Conversations program	9,175	-	9,175
Research	3,552	-	3,552
RDG	18,630	-	18,630
Alliances	-	13,608	13,608
Other	40,631	3,208	43,839
<b>Total</b>	<u>195,207</u>	<u>31,152</u>	<u>226,359</u>
<b>NET INCOME/(EXPENDITURE)</b>	(130,097)	(6,387)	(136,484)
<b>RECONCILIATION OF FUNDS</b>			
Total funds brought forward	212,009	116,531	328,540
<b>TOTAL FUNDS CARRIED FORWARD</b>	<u>81,912</u>	<u>110,144</u>	<u>192,056</u>

**8. VOLUNTEERS**

The charity heavily relies upon the many medical professionals who donate their time to help run the various charitable activities undertaken. It is not possible to accurately calculate the value of the services contributed by these volunteers and therefore the numbers do not reflect either the income or expenditure, however it is thought to be in the region of £230,000.

**9. DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR**

	<b>2024</b>	2023
	£	£
Other debtors	<b>51,632</b>	113,534

Included within other debtors is a balance of £49,997 (2023 - £103,109) in respect of funds held by Paypal.

**10. CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR**

	<b>2024</b>	2023
	£	£
Trade creditors	-	2,268
Accrued expenses	<b>6,780</b>	4,584
	<b>6,780</b>	6,852

**11. MOVEMENT IN FUNDS**

	At 1/9/23	Net movement in funds	At 31/8/24
	£	£	£
<b>Unrestricted funds</b>			
General fund	<b>81,912</b>	<b>(50,979)</b>	<b>30,933</b>
<b>Restricted funds</b>			
Novartis Pharmaceuticals Corporation	<b>103,090</b>	<b>(11,840)</b>	<b>91,250</b>
Pfizer Grant	<b>7,054</b>	<b>(7,054)</b>	-
Incyte - Alliance/Cure Programs	-	<b>111,218</b>	<b>111,218</b>
Patient Education	-	<b>30,127</b>	<b>30,127</b>
	<b>110,144</b>	<b>122,451</b>	<b>232,595</b>
<b>TOTAL FUNDS</b>	<b>192,056</b>	<b>71,472</b>	<b>263,528</b>

**11. MOVEMENT IN FUNDS - continued**

Net movement in funds, included in the above are as follows:

	Incoming resources £	Resources expended £	Movement in funds £
<b>Unrestricted funds</b>			
General fund	<b>96,227</b>	<b>(147,206)</b>	<b>(50,979)</b>
<b>Restricted funds</b>			
Novartis Pharmaceuticals Corporation	<b>1</b>	<b>(11,841)</b>	<b>(11,840)</b>
Takeda Oncology	<b>31,097</b>	<b>(31,097)</b>	-
Pfizer Grant	-	<b>(7,054)</b>	<b>(7,054)</b>
Incyte - Alliance/Cure Programs	<b>117,088</b>	<b>(5,870)</b>	<b>111,218</b>
Patient Education	<b>50,532</b>	<b>(20,405)</b>	<b>30,127</b>
Novartis RDG	<b>15,549</b>	<b>(15,549)</b>	-
	<b>214,267</b>	<b>(91,816)</b>	<b>122,451</b>
<b>TOTAL FUNDS</b>	<b>310,494</b>	<b>(239,022)</b>	<b>71,472</b>

**Comparatives for movement in funds**

	At 1/9/22 £	Net movement in funds £	At 31/8/23 £
<b>Unrestricted funds</b>			
General fund	212,009	(130,097)	81,912
<b>Restricted funds</b>			
Novartis Pharmaceuticals Corporation	111,626	(8,536)	103,090
Novartis Pharma AG	4,905	(4,905)	-
Pfizer Grant	-	7,054	7,054
	<b>116,531</b>	<b>(6,387)</b>	<b>110,144</b>
<b>TOTAL FUNDS</b>	<b>328,540</b>	<b>(136,484)</b>	<b>192,056</b>

Comparative net movement in funds, included in the above are as follows:

	Incoming resources £	Resources expended £	Movement in funds £
<b>Unrestricted funds</b>			
General fund	65,110	(195,207)	(130,097)
<b>Restricted funds</b>			
Novartis Pharmaceuticals Corporation	-	(8,536)	(8,536)
Novartis Patient	4,103	(4,103)	-
Novartis Pharma AG	-	(4,905)	(4,905)
Pfizer Grant	20,662	(13,608)	7,054
	<b>24,765</b>	<b>(31,152)</b>	<b>(6,387)</b>
<b>TOTAL FUNDS</b>	<b>89,875</b>	<b>(226,359)</b>	<b>(136,484)</b>

**THE INTERNATIONAL CML FOUNDATION**

**NOTES TO THE FINANCIAL STATEMENTS - continued  
FOR THE YEAR ENDED 31ST AUGUST 2024**

**11. MOVEMENT IN FUNDS - continued**

A current year 12 months and prior year 12 months combined position is as follows:

	At 1/9/22 £	Net movement in funds £	At 31/8/24 £
<b>Unrestricted funds</b>			
General fund	212,009	(181,076)	30,933
<b>Restricted funds</b>			
Novartis Pharmaceuticals Corporation	111,626	(20,376)	91,250
Novartis Pharma AG	4,905	(4,905)	-
Incyte - Alliance/Cure Programs	-	111,218	111,218
Patient Education	-	30,127	30,127
	<u>116,531</u>	<u>116,064</u>	<u>232,595</u>
<b>TOTAL FUNDS</b>	<u>328,540</u>	<u>(65,012)</u>	<u>263,528</u>

A current year 12 months and prior year 12 months combined net movement in funds, included in the above are as follows:

	Incoming resources £	Resources expended £	Movement in funds £
<b>Unrestricted funds</b>			
General fund	161,337	(342,413)	(181,076)
<b>Restricted funds</b>			
Novartis Pharmaceuticals Corporation	1	(20,377)	(20,376)
Takeda Oncology	31,097	(31,097)	-
Novartis Patient	4,103	(4,103)	-
Novartis Pharma AG	-	(4,905)	(4,905)
Pfizer Grant	20,662	(20,662)	-
Incyte - Alliance/Cure Programs	117,088	(5,870)	111,218
Patient Education	50,532	(20,405)	30,127
Novartis RDG	15,549	(15,549)	-
	<u>239,032</u>	<u>(122,968)</u>	<u>116,064</u>
<b>TOTAL FUNDS</b>	<u>400,369</u>	<u>(465,381)</u>	<u>(65,012)</u>

**12. RELATED PARTY DISCLOSURES**

There were no related party transactions for the year ended 31st August 2024.

**THE INTERNATIONAL CML FOUNDATION**

England & Wales - Charity number 1132984

---

# Accounts

---

REGISTERED COMPANY NUMBER: 06996068 (England and Wales)  
REGISTERED CHARITY NUMBER: 1132984

REPORT OF THE TRUSTEES AND  
UNAUDITED FINANCIAL STATEMENTS  
FOR THE YEAR ENDED 31ST AUGUST 2022  
FOR  
THE INTERNATIONAL CML FOUNDATION

Gibbons Mannington & Phipps LLP  
Chartered Accountants  
20 Eversley Road  
Bexhill-on-Sea  
East Sussex  
TN40 1HE

THE INTERNATIONAL CML FOUNDATION

CONTENTS OF THE FINANCIAL STATEMENTS  
FOR THE YEAR ENDED 31ST AUGUST 2022

---

	Page
Report of the Trustees	1 to 4
Independent Examiner's Report	5
Statement of Financial Activities	6
Balance Sheet	7
Notes to the Financial Statements	8 to 15

---

REPORT OF THE TRUSTEES  
FOR THE YEAR ENDED 31ST AUGUST 2022

---

The trustees who are also directors of the charity for the purposes of the Companies Act 2006, present their report with the financial statements of the charity for the year ended 31st August 2022. The trustees have adopted the provisions of Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2019).

#### OBJECTIVES AND ACTIVITIES

##### Objectives and aims

The object of the Foundation is the advancement of health by the improvement of the treatment in all parts of the world of chronic myeloid leukaemia and related diseases (together "CML") and for the purpose of carrying out those general objects, the primary objects of the Foundation are in particular: -

- (i) to improve clinical practice and disease monitoring in the treatment of CML
- (ii) to support, encourage and promote research into the causes, prevention, study and treatment of CML
- (iii) to promote and support the education of and disseminate knowledge amongst clinicians, scientists, health professionals and patients in matters concerning CML
- (iv) to promote, foster and co-ordinate collaboration that is particularly (but not exclusively) international and is not only in the areas and activities of clinical practice disease monitoring and research into CML but also in any area or activity which is or may be conducive to the acceleration of the control and/or cure of CML
- (v) to promote, set up, establish and support and share and exchange knowledge with other organisations whose objects are similar to these general or primary objects
- (vi) to assist or promote any other charitable purposes which are related to these general and primary objects.

##### Significant activities

In furtherance of the objects, the Foundation has the following powers: -

- (i) to promote or carry out research
- (ii) to provide advice
- (iii) to give and exchange information and advice and promote learning, study and research
- (iv) to commission, publish, distribute and contribute to papers, books, periodicals, reports, leaflets, posters and other publications of any description
- (v) to hold, attend and sponsor conferences, meetings, lectures, exhibitions and discussions
- (vi) to raise funds and to apply for and solicit grants from pharmaceutical companies anywhere in the world.

##### Public benefit

The Trustees have considered their duty to have due regard to public benefit guidance published by the Commission and in their opinion, the foregoing report on the achievements and performance demonstrates that they have complied therewith.

REPORT OF THE TRUSTEES  
FOR THE YEAR ENDED 31ST AUGUST 2022

---

## ACHIEVEMENT AND PERFORMANCE

### Charitable activities

The iCMLf continued to lead the CML community with the COVID-19 & CML case collection, analysis and treatment guidance. There are 3 iCMLf international research projects underway. The online webinars continue for COVID guidance and other key areas of CML management. With the launch of the iCMLf Knowledge Centre, a new educational program specifically for non-academic centres, the iCMLf continues to be at the forefront of CML education and enhancing patient management around the world.

### Global Research Programs

Covid-19 (CANDID) study - This remained a significant focus for the year. The completed dataset included 1,050 cases from 900 physicians in 58 countries. The data is widely respected with 4 further presentations at international conferences.

### Cure Consortium

iCMLf Treatment Free Remission Alliance - Global TFR registry began in February 2022. 24 sites from 16 countries and 2,900 potential datasets. Site initiation remains ongoing.

iCMLf Genomic Alliance - The iCMLf genomics project 'Clonal Hierarchy in CML' data upload is underway. 12 sites from 10 countries participating.

### Online CML Education

iCMLf Clinical Conversations - 9 discussions with 16 experts from 10 countries with over 300 live participants and 3,000 online participants.

### iCMLf Knowledge Centre

The Knowledge Centre is an interactive, online resource providing educational content for holistic CML patient management. 33 speakers from 16 countries with 1,600 users.

## FINANCIAL REVIEW

### Financial position

The financial position of the International CML Foundation remains solid.

### Principal funding sources

The iCMLf works closely with industry and community partners to secure unrestricted grants and sponsorship for our programs and activities. The iCMLf requests donations through the iCMLf website.

### Reserves policy

The reserves at the year end were £328,540 (2021 - £305,347). It is the policy of the Trustees to maintain sufficient reserves to ensure the day to day running of the Foundation. The level of reserves and current financial commitments are reviewed regularly at Trustees' meetings. The Foundation plans to hold a minimum of £150,000 as reserve funding. This is the amount for the foundation to operate without further income/outgoings for one year.

## FUTURE PLANS

While maintaining the expert best practice and education initiatives of the Foundation, we aim to harness global network of the iCMLf to enhance research into potential cures for CML. The iCMLf Genomics Alliance will access the wealth of genomic information that is generated in local CML research projects by facilitating data assimilation and samples exchanges through an international data collection platform. Combining many data sets and facilitating global collaborative studies will enable us to develop a baseline predictor of adverse outcomes.

The iCMLf TFR Alliance looks to define biomarkers for treatment discontinuation and a functional cure of CML.

The CML and COVID-19 retrospective case analysis will provide data for physicians to base treatment decisions on as the pandemic continues.

## STRUCTURE, GOVERNANCE AND MANAGEMENT

### Governing document

The charity is controlled by its governing document, a deed of trust, and constitutes a limited company, limited by guarantee, as defined by the Companies Act 2006.

REPORT OF THE TRUSTEES  
FOR THE YEAR ENDED 31ST AUGUST 2022

---

#### STRUCTURE, GOVERNANCE AND MANAGEMENT

##### Recruitment and appointment of new trustees

The power of appointing new or additional Trustees is vested in the existing Trustees. Prior to appointment, new Trustees would be introduced to the workings of the Foundation and advised of their responsibilities.

##### Organisational structure

The chief executive reports to the ten iCMLf Directors, specifically the iCMLf Chairman.

The operational team; Communications Director, Communications Manager, Digital Media Officer, and ERSAP Program Coordinator, report to the chief executive.

Strategic direction, financial review and budget approval are set at an annual iCMLf directors meeting in September/October each year. Further directors planning and discussion meetings are held quarterly.

Strategic planning is assisted with an annual advisors meeting. This includes the thirteen physicians, scientific and patient advisors and members from the 36 countries with iCMLf National Representatives.

The operational team meets every 6-8 weeks. The communications director/communications manager meet biweekly with the chief executive respectively and the program coordinator and chief executive meet weekly for business planning. The chief executive and iCMLf Chairman meet monthly.

Decisions are escalated from the operational team to the chief executive, iCMLf Chairman and iCMLf Board of Directors according to scale and impact.

#### REFERENCE AND ADMINISTRATIVE DETAILS

Registered Company number  
06996068 (England and Wales)

Registered Charity number  
1132984

Registered office  
20 Eversley Road  
Bexhill-on-Sea  
East Sussex  
TN40 1HE

##### Trustees

Professor T P Hughes  
Professor M Baccarani Professor (resigned 20/12/2021)  
Professor J Cortes Professor  
Professor B Druker Professor  
Professor A Hochhaus Professor  
Professor J Radich Professor  
Professor C Schiffer Professor  
Professor J F Apperley DM FRCP/Path Professor  
Professor M Mauro Professor  
Professor G Saglio Professor

Company Secretary  
Ms N C Evans

Independent Examiner  
R Appleyard FCA  
Gibbons Mannington & Phipps LLP  
Chartered Accountants  
20 Eversley Road  
Bexhill-on-Sea  
East Sussex  
TN40 1HE

---

THE INTERNATIONAL CML FOUNDATION (REGISTERED NUMBER: 06996068)

REPORT OF THE TRUSTEES  
FOR THE YEAR ENDED 31ST AUGUST 2022

---

REFERENCE AND ADMINISTRATIVE DETAILS

Bankers

HSBC Bank, 152 Portobello Road, London, W11 2EA

This report has been prepared in accordance with the special provisions of Part 15 of the Companies Act 2006 relating to small companies.

Approved by order of the board of trustees on 11th May 2023 and signed on its behalf by:

Professor T P Hughes - Trustee

Independent examiner's report to the trustees of The International CML Foundation ('the Company')

I report to the charity trustees on my examination of the accounts of the Company for the year ended 31st August 2022.

#### Responsibilities and basis of report

As the charity's trustees of the Company (and also its directors for the purposes of company law) you are responsible for the preparation of the accounts in accordance with the requirements of the Companies Act 2006 ('the 2006 Act').

Having satisfied myself that the accounts of the Company are not required to be audited under Part 16 of the 2006 Act and are eligible for independent examination, I report in respect of my examination of your charity's accounts as carried out under Section 145 of the Charities Act 2011 ('the 2011 Act'). In carrying out my examination I have followed the Directions given by the Charity Commission under Section 145(5) (b) of the 2011 Act.

#### Independent examiner's statement - matters of concern identified

I have completed my examination.

I draw attention to Note 10 of the accounts, regarding the balance of funds held by Paypal. Whilst nothing has come to my attention to indicate that the balance shown in the accounts is incorrect, it has not been possible to verify the balance of funds held in the Paypal account as part of my examination due to the fact that the charity is currently unable to access the account.

I confirm that no other matters have come to my attention in connection with the examination giving me reasonable cause to believe that in any material respect:

1. accounting records were not kept in respect of the Company as required by Section 386 of the 2006 Act; or
2. the accounts do not accord with those records; or
3. the accounts do not comply with the accounting requirements of Section 396 of the 2006 Act other than any requirement that the accounts give a true and fair view which is not a matter considered as part of an independent examination; and
4. the accounts have not been prepared in accordance with the methods and principles of the Statement of Recommended Practice for accounting and reporting by charities (applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102)).

I confirm that there are no other matters to which your attention should be drawn to enable a proper understanding of the accounts to be reached.

R Appleyard FCA

Gibbons Mannington & Phipps LLP  
Chartered Accountants  
20 Eversley Road  
Bexhill-on-Sea  
East Sussex  
TN40 1HE

16th May 2023

THE INTERNATIONAL CML FOUNDATION

STATEMENT OF FINANCIAL ACTIVITIES  
FOR THE YEAR ENDED 31ST AUGUST 2022

	Notes	Unrestricted funds £	Restricted funds £	2022 Total funds £	2021 Total funds £
<b>INCOME AND ENDOWMENTS FROM</b>					
Donations and legacies		119,414	66,043	185,457	75,107
Other trading activities	2	279	-	279	-
Other income	3	23,495	-	23,495	(5,904)
<b>Total</b>		<u>143,188</u>	<u>66,043</u>	<u>209,231</u>	<u>69,203</u>
<b>EXPENDITURE ON</b>					
<b>Charitable activities</b>					
Diagnosis & testing		-	11,784	11,784	-
Scientific meetings		5,926	-	5,926	696
ICMLF Forum		17	-	17	3,402
Communications		31,816	372	32,188	29,031
Fundraising		12,448	-	12,448	8,913
Cure Consortium		14,102	-	14,102	5,147
Candid		-	23,304	23,304	35,113
Knowledge Centre		(20,073)	61,138	41,065	21,529
Conversations		23,403	1,559	24,962	28,938
Other		20,242	-	20,242	13,891
<b>Total</b>		<u>87,881</u>	<u>98,157</u>	<u>186,038</u>	<u>146,660</u>
<b>NET INCOME/(EXPENDITURE)</b>		55,307	(32,114)	23,193	(77,457)
<b>RECONCILIATION OF FUNDS</b>					
Total funds brought forward		156,702	148,645	305,347	382,804
<b>TOTAL FUNDS CARRIED FORWARD</b>		<u>212,009</u>	<u>116,531</u>	<u>328,540</u>	<u>305,347</u>

The notes form part of these financial statements

BALANCE SHEET  
31ST AUGUST 2022

	Notes	Unrestricted funds £	Restricted funds £	2022 Total funds £	2021 Total funds £
<b>CURRENT ASSETS</b>					
Debtors	10	102,793	-	102,793	86,793
Cash at bank and in hand		113,584	116,531	230,115	222,826
		<u>216,377</u>	<u>116,531</u>	<u>332,908</u>	<u>309,619</u>
<b>CREDITORS</b>					
Amounts falling due within one year	11	(4,368)	-	(4,368)	(4,272)
		<u>212,009</u>	<u>116,531</u>	<u>328,540</u>	<u>305,347</u>
<b>NET CURRENT ASSETS</b>					
		<u>212,009</u>	<u>116,531</u>	<u>328,540</u>	<u>305,347</u>
<b>TOTAL ASSETS LESS CURRENT LIABILITIES</b>					
		<u>212,009</u>	<u>116,531</u>	<u>328,540</u>	<u>305,347</u>
<b>NET ASSETS</b>					
		<u>212,009</u>	<u>116,531</u>	<u>328,540</u>	<u>305,347</u>
<b>FUNDS</b>					
	12				
Unrestricted funds				212,009	156,702
Restricted funds				116,531	148,645
				<u>328,540</u>	<u>305,347</u>
<b>TOTAL FUNDS</b>					
				<u>328,540</u>	<u>305,347</u>

The charitable company is entitled to exemption from audit under Section 477 of the Companies Act 2006 for the year ended 31st August 2022.

The members have not required the company to obtain an audit of its financial statements for the year ended 31st August 2022 in accordance with Section 476 of the Companies Act 2006.

The trustees acknowledge their responsibilities for

- ensuring that the charitable company keeps accounting records that comply with Sections 386 and 387 of the Companies Act 2006 and
- preparing financial statements which give a true and fair view of the state of affairs of the charitable company as at the end of each financial year and of its surplus or deficit for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the charitable company.

These financial statements have been prepared in accordance with the provisions applicable to charitable companies subject to the small companies regime.

The financial statements were approved by the Board of Trustees and authorised for issue on 11th May 2023 and were signed on its behalf by:

T P Hughes - Trustee

1. ACCOUNTING POLICIES

Basis of preparing the financial statements

The financial statements of the charitable company, which is a public benefit entity under FRS 102, have been prepared in accordance with the Charities SORP (FRS 102) 'Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2019)', Financial Reporting Standard 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland' and the Companies Act 2006. The financial statements have been prepared under the historical cost convention.

Income

Items of income are recognised and included in the accounts when all of the following criteria are met:

- The charity or its subsidiary have entitlement to the funds;
- any performance conditions attached to the item(s) of income have been met or are fully within the control of the charity or its subsidiary;
- there is sufficient certainty that receipt of the income is considered probable; and
- the amount can be measured reliably.

Expenditure

Liabilities are recognised as expenditure as soon as there is a legal or constructive obligation committing the charity to that expenditure, it is probable that a transfer of economic benefits will be required in settlement and the amount of the obligation can be measured reliably. Expenditure is accounted for on an accruals basis and has been classified under headings that aggregate all cost related to the category. Where costs cannot be directly attributed to particular headings they have been allocated to activities on a basis consistent with the use of resources.

Debtors

Debtors are recognised at the settlement amount due after any trade discount offered. Prepayments are valued at the amount prepaid after taking account of any trade discounts due.

Creditors and provisions

Creditors and provisions are recognised where the charity has a present obligation resulting from a past event that will probably result in the transfer of funds to a third party and the amount due to settle the obligation can be measured or estimated reliably. Creditors and provisions are normally recognised at their settlement amount after allowing for any trade discounts due.

Taxation

The charity is exempt from corporation tax on its charitable activities.

Fund accounting

Unrestricted funds can be used in accordance with the charitable objectives at the discretion of the trustees.

Restricted funds can only be used for particular restricted purposes within the objects of the charity. Restrictions arise when specified by the donor or when funds are raised for particular restricted purposes.

Further explanation of the nature and purpose of each fund is included in the notes to the financial statements.

Foreign currencies

Assets and liabilities in foreign currencies are translated into sterling at the rates of exchange ruling at the balance sheet date. Transactions in foreign currencies are translated into sterling at the rate of exchange ruling at the date of transaction. Exchange differences are taken into account in arriving at the operating result and are shown as other income.

2. OTHER TRADING ACTIVITIES

The iCMLf request donations through the iCMLf website.

3. OTHER INCOME

Other income consists of the profit on foreign currency exchange in accordance with the accounting policy on foreign exchange transactions.

4. SUPPORT COSTS

	Management fees £	Finance £	Other £	Governance costs £	Totals £
Other resources expended	17,586	268	567	1,821	20,242
Diagnosis & testing	11,784	-	-	-	11,784
Scientific meetings	1,785	-	-	-	1,785
Communications	27,990	-	-	1,456	29,446
Fundraising	5,034	17	1,966	-	7,017
Cure Consortium	10,926	-	-	-	10,926
Candid	22,403	-	-	-	22,403
Knowledge Centre	36,736	-	-	1,456	38,192
Conversations	23,501	-	-	1,456	24,957
	<u>157,745</u>	<u>285</u>	<u>2,533</u>	<u>6,189</u>	<u>166,752</u>

Support costs, included in the above, are as follows:

Management fees

	Other resources expended £	Diagnosis & testing £	Scientific meetings £
Management & admin	<u>17,586</u>	<u>11,784</u>	<u>1,785</u>
	Communications £	Fundraising £	Cure Consortium £
Management & admin	<u>27,990</u>	<u>5,034</u>	<u>10,926</u>
	Knowledge Centre £	Conversations £	2022 Total activities £
Management & admin	<u>36,736</u>	<u>23,501</u>	<u>157,745</u>
			2021 Total activities £
			<u>132,913</u>

4. SUPPORT COSTS - continued  
Finance

			2022	2021
	Other resources expended	Fundraising	Total activities	Total activities
	£	£	£	£
Bank charges	<u>268</u>	<u>17</u>	<u>285</u>	<u>395</u>

## Other

			2022	2021
	Other resources expended	Fundraising	Total activities	Total activities
	£	£	£	£
Sundry office costs	<u>567</u>	<u>1,966</u>	<u>2,533</u>	<u>2,631</u>

## Governance costs

	Other resources expended	Communications	Knowledge Centre
	£	£	£
Accountancy - Independent examination fee	-	1,456	1,456
Legal and Professional fees	<u>1,821</u>	<u>-</u>	<u>-</u>
	<u>1,821</u>	<u>1,456</u>	<u>1,456</u>

		2022	2021
	Conversations	Total activities	Total activities
	£	£	£
Accountancy - Independent examination fee	1,456	4,368	4,242
Legal and Professional fees	<u>-</u>	<u>1,821</u>	<u>-</u>
	<u>1,456</u>	<u>6,189</u>	<u>4,242</u>

## 5. NET INCOME/(EXPENDITURE)

Net income/(expenditure) is stated after charging/(crediting):

	2022	2021
	£	£
Accountancy - Independent examination fee	<u>4,368</u>	<u>4,242</u>

## 6. TRUSTEES' REMUNERATION AND BENEFITS

There were no trustees' remuneration or other benefits for the year ended 31st August 2022 nor for the year ended 31st August 2021.

## Trustees' expenses

There were no trustees' expenses paid for the year ended 31st August 2022 nor for the year ended 31st August 2021.

## 7. STAFF COSTS

The average monthly number of employees during the year was as follows:

	2022	2021
Charitable activities	<u>4</u>	<u>4</u>

The number of employees whose employee benefits (excluding employer pension costs) exceeded £60,000 was:

	2022	2021
£80,001 - £90,000	<u>1</u>	<u>1</u>

## 8. COMPARATIVES FOR THE STATEMENT OF FINANCIAL ACTIVITIES

	Unrestricted funds £	Restricted funds £	Total funds £
INCOME AND ENDOWMENTS FROM			
Donations and legacies	8,459	66,648	75,107
Other income	<u>(5,904)</u>	-	<u>(5,904)</u>
Total	<u>2,555</u>	<u>66,648</u>	<u>69,203</u>
EXPENDITURE ON			
Charitable activities			
Scientific meetings	696	-	696
ICMLF Forum	3,402	-	3,402
Communications	1,414	27,617	29,031
Fundraising	5,818	3,095	8,913
Cure Consortium	-	5,147	5,147
Candid	39	35,074	35,113
Knowledge Centre	21,529	-	21,529
Conversations	27,098	1,840	28,938
Other	<u>13,891</u>	-	<u>13,891</u>
Total	<u>73,887</u>	<u>72,773</u>	<u>146,660</u>
NET INCOME/(EXPENDITURE)	(71,332)	(6,125)	(77,457)
RECONCILIATION OF FUNDS			
Total funds brought forward	228,033	154,771	382,804

## 8. COMPARATIVES FOR THE STATEMENT OF FINANCIAL ACTIVITIES - continued

	Unrestricted funds £	Restricted funds £	Total funds £
TOTAL FUNDS CARRIED FORWARD	<u>156,701</u>	<u>148,646</u>	<u>305,347</u>

## 9. VOLUNTEERS

The charity heavily relies upon the many medical professionals who donate their time to help run the various charitable activities undertaken. It is not possible to accurately calculate the value of the services contributed by these volunteers and therefore the numbers do not reflect either the income or expenditure, however it is thought to be in the region of £230,000.

## 10. DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR

	2022 £	2021 £
Other debtors	<u>102,793</u>	<u>86,793</u>

Included within other debtors is a balance of £88,015 in respect of funds held by Paypal. As a result of a change of personnel, the account access is being transferred by Paypal, and until this process has been completed the charity cannot transfer or use these funds.

## 11. CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR

	2022 £	2021 £
Accrued expenses	<u>4,368</u>	<u>4,272</u>

## 12. MOVEMENT IN FUNDS

	At 1/9/21 £	Net movement in funds £	At 31/8/22 £
Unrestricted funds			
General fund	156,702	55,307	212,009
Restricted funds			
Novartis Pharmaceuticals Corporation	123,410	(11,784)	111,626
Pfizer	24,863	(24,863)	-
Novartis Patient	372	(372)	-
Novartis Pharma AG	-	4,905	4,905
	<u>148,645</u>	<u>(32,114)</u>	<u>116,531</u>
TOTAL FUNDS	<u>305,347</u>	<u>23,193</u>	<u>328,540</u>

## 12. MOVEMENT IN FUNDS - continued

Net movement in funds, included in the above are as follows:

	Incoming resources £	Resources expended £	Movement in funds £
Unrestricted funds			
General fund	143,188	(87,881)	55,307
Restricted funds			
Novartis Pharmaceuticals Corporation	-	(11,784)	(11,784)
Pfizer	-	(24,863)	(24,863)
Novartis Patient	-	(372)	(372)
Novartis Pharma AG	66,043	(61,138)	4,905
	<u>66,043</u>	<u>(98,157)</u>	<u>(32,114)</u>
TOTAL FUNDS	<u>209,231</u>	<u>(186,038)</u>	<u>23,193</u>

Comparatives for movement in funds

	At 1/9/20 £	Net movement in funds £	At 31/8/21 £
Unrestricted funds			
General fund	224,118	(67,416)	156,702
Cepheid	3,915	(3,915)	-
	<u>228,033</u>	<u>(71,331)</u>	<u>156,702</u>
Restricted funds			
Novartis Pharmaceuticals Corporation	123,410	-	123,410
Pfizer	23,118	1,745	24,863
Novartis Killi Climb	8,243	(8,243)	-
Novartis Patient	-	372	372
	<u>154,771</u>	<u>(6,126)</u>	<u>148,645</u>
TOTAL FUNDS	<u>382,804</u>	<u>(77,457)</u>	<u>305,347</u>

## 12. MOVEMENT IN FUNDS - continued

Comparative net movement in funds, included in the above are as follows:

	Incoming resources £	Resources expended £	Movement in funds £
Unrestricted funds			
General fund	2,555	(69,971)	(67,416)
Cepheid	-	(3,915)	(3,915)
	<u>2,555</u>	<u>(73,886)</u>	<u>(71,331)</u>
Restricted funds			
Takeda Oncology	29,457	(29,457)	-
Pfizer	36,819	(35,074)	1,745
Novartis Killi Climb	-	(8,243)	(8,243)
Novartis Patient	372	-	372
	<u>66,648</u>	<u>(72,774)</u>	<u>(6,126)</u>
TOTAL FUNDS	<u>69,203</u>	<u>(146,660)</u>	<u>(77,457)</u>

A current year 12 months and prior year 12 months combined position is as follows:

	At 1/9/20 £	Net movement in funds £	At 31/8/22 £
Unrestricted funds			
General fund	224,118	(12,109)	212,009
Cepheid	3,915	(3,915)	-
	<u>228,033</u>	<u>(16,024)</u>	<u>212,009</u>
Restricted funds			
Novartis Pharmaceuticals Corporation	123,410	(11,784)	111,626
Pfizer	23,118	(23,118)	-
Novartis Killi Climb	8,243	(8,243)	-
Novartis Pharma AG	-	4,905	4,905
	<u>154,771</u>	<u>(38,240)</u>	<u>116,531</u>
TOTAL FUNDS	<u>382,804</u>	<u>(54,264)</u>	<u>328,540</u>

## 12. MOVEMENT IN FUNDS - continued

A current year 12 months and prior year 12 months combined net movement in funds, included in the above are as follows:

	Incoming resources £	Resources expended £	Movement in funds £
Unrestricted funds			
General fund	145,743	(157,852)	(12,109)
Cepheid	-	(3,915)	(3,915)
	<u>145,743</u>	<u>(161,767)</u>	<u>(16,024)</u>
Restricted funds			
Novartis Pharmaceuticals Corporation	-	(11,784)	(11,784)
Takeda Oncology	29,457	(29,457)	-
Pfizer	36,819	(59,937)	(23,118)
Novartis Killi Climb	-	(8,243)	(8,243)
Novartis Patient	372	(372)	-
Novartis Pharma AG	66,043	(61,138)	4,905
	<u>132,691</u>	<u>(170,931)</u>	<u>(38,240)</u>
TOTAL FUNDS	<u><u>278,434</u></u>	<u><u>(332,698)</u></u>	<u><u>(54,264)</u></u>

## 13. RELATED PARTY DISCLOSURES

There were no related party transactions for the year ended 31st August 2022.

**THE INTERNATIONAL CML FOUNDATION**

England & Wales - Charity number 1132984

---

# Accounts

---

**REPORT OF THE TRUSTEES AND  
UNAUDITED FINANCIAL STATEMENTS  
FOR THE YEAR ENDED 31ST AUGUST 2021  
FOR  
THE INTERNATIONAL CML FOUNDATION**

Gibbons Mannington & Phipps LLP  
Chartered Accountants  
20 Eversley Road  
Bexhill-on-Sea  
East Sussex  
TN40 1HE

	<b>Page</b>
<b>Report of the Trustees</b>	1 to 4
<b>Independent Examiner's Report</b>	5
<b>Statement of Financial Activities</b>	6
<b>Balance Sheet</b>	7
<b>Notes to the Financial Statements</b>	8 to 15

---

**REPORT OF THE TRUSTEES  
FOR THE YEAR ENDED 31ST AUGUST 2021**

---

The trustees who are also directors of the charity for the purposes of the Companies Act 2006, present their report with the financial statements of the charity for the year ended 31st August 2021. The trustees have adopted the provisions of Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2019).

**OBJECTIVES AND ACTIVITIES**

**Objectives and aims**

The object of the Foundation is the advancement of health by the improvement of the treatment in all parts of the world of chronic myeloid leukaemia and related diseases (together "CML") and for the purpose of carrying out those general objects, the primary objects of the Foundation are in particular:-

- (i) to improve clinical practice and disease monitoring in the treatment of CML
- (ii) to support, encourage and promote research into the causes, prevention, study and treatment of CML
- (iii) to promote and support the education of and disseminate knowledge amongst clinicians, scientists, health professionals and patients in matters concerning CML
- (iv) to promote, foster and co-ordinate collaboration that is particularly (but not exclusively) international and is not only in the areas and activities of clinical practice disease monitoring and research into CML but also in any area or activity which is or may be conducive to the acceleration of the control and/or cure of CML
- (v) to promote, set up, establish and support and share and exchange knowledge with other organisations whose objects are similar to these general or primary objects
- (vi) to assist or promote any other charitable purposes which are related to these general and primary objects.

**Significant activities**

In furtherance of the objects, the Foundation has the following powers:-

- (i) to promote or carry out research
- (ii) to provide advice
- (iii) to give and exchange information and advice and promote learning, study and research
- (iv) to commission, publish, distribute and contribute to papers, books, periodicals, reports, leaflets, posters and other publications of any description
- (v) to hold, attend and sponsor conferences, meetings, lectures, exhibitions and discussions
- (vi) to raise funds and to apply for and solicit grants from pharmaceutical companies anywhere in the world.

**Public benefit**

The Trustees have considered their duty to have due regard to public benefit guidance published by the Commission and in their opinion, the foregoing report on the achievements and performance demonstrates that they have complied therewith.

**REPORT OF THE TRUSTEES  
FOR THE YEAR ENDED 31ST AUGUST 2021**

---

**ACHIEVEMENT AND PERFORMANCE**

**Charitable activities**

The iCMLf has led the CML community with the COVID-19 case collection and guidance. We have 3 international research projects underway and by implementing the online webinars, first for COVID and now continuing onto other areas of CML management, the iCMLf continues to be at the forefront of CML education and enhancing patient management.

CANDID case collection & publications - This has remained the significant focus with now over 900 cases from 56 countries. The data is widely respected with an oral presentation at the American Hematology meeting in 2020 and abstracts submitted to two further international conferences.

**Online CML Education**

Clinical Conversations - 16 discussions in 5 languages, with over 700 live participants and 5,600 online participants.

**Cure Consortium**

Treatment Free Remission Alliance - The Swedish team was appointed to lead the global data registry and the initial needs assessment survey is underway. A trials in progress abstract was presented at an international CML congress.

iCMLf Genomic Alliance - Harmony project - With 41 collaborators from 21 countries, the iCMLf is leading the CML community to align CML data submission into the European Harmony big data project. The iCMLf genomics project 'Clonal Hierarchy in CML' has been accepted by Harmony and site selection is underway.

**FINANCIAL REVIEW**

**Financial position**

The financial position of the International CML Foundation remains solid.

**Principal funding sources**

The iCMLf works closely with industry and community partners to secure unrestricted grants and sponsorship for our programs and activities. The iCMLf requests donations through the iCMLf website.

**Reserves policy**

The reserves at the year end were £305,347 (2020 - £382,804). It is the policy of the Trustees to maintain sufficient reserves to ensure the day to day running of the Foundation. The level of reserves and current financial commitments are reviewed regularly at Trustees' meetings. The Foundation plans to hold a minimum of £150,000 as reserve funding. This is the amount for the foundation to operate without further income/outgoings for one year.

**FUTURE PLANS**

While maintaining the expert best practice and education initiatives of the Foundation, we aim to harness global network of the iCMLf to enhance research into potential cures for CML. The iCMLf Genomics Alliance will access the wealth of genomic information that is generated in local CML research projects by facilitating data assimilation and samples exchanges through an international data collection platform. Combining many data sets and facilitating global collaborative studies will enable us to develop a baseline predictor of adverse outcomes.

The iCMLf TFR Alliance looks to define biomarkers for treatment discontinuation and a functional cure of CML.

The CML and COVID-19 retrospective case analysis will provide data for physicians to base treatment decisions on as the pandemic continues.

**STRUCTURE, GOVERNANCE AND MANAGEMENT**

**Governing document**

The charity is controlled by its governing document, a deed of trust, and constitutes a limited company, limited by guarantee, as defined by the Companies Act 2006.

**REPORT OF THE TRUSTEES  
FOR THE YEAR ENDED 31ST AUGUST 2021**

---

**STRUCTURE, GOVERNANCE AND MANAGEMENT**

**Recruitment and appointment of new trustees**

The power of appointing new or additional Trustees is vested in the existing Trustees. Prior to appointment, new Trustees would be introduced to the workings of the Foundation and advised of their responsibilities.

**Organisational structure**

The chief executive reports to the ten iCMLf Directors, specifically the iCMLf Chairman.

The operational team; Communications Director, Digital Media Officer, and ERSAP Program Coordinator, report to the chief executive.

Strategic direction, financial review and budget approval are set at an annual iCMLf directors meeting in September/October each year. Further directors planning and discussion meetings are held quarterly.

Strategic planning is assisted with an annual advisors meeting. This includes the thirteen physicians, scientific and patient advisors and members from the 36 countries with iCMLf National Representatives.

The operational team meets every 6-8 weeks. The communications director and chief executive meet biweekly and the program coordinator and chief executive meet weekly for business planning. The chief executive and iCMLf Chairman meet monthly.

Decisions are escalated from the operational team to the chief executive, iCMLf Chairman and iCMLf Board of Directors according to scale and impact.

**REFERENCE AND ADMINISTRATIVE DETAILS**

**Registered Company number**

06996068 (England and Wales)

**Registered Charity number**

1132984

**Registered office**

20 Eversley Road  
Bexhill-on-Sea  
East Sussex  
TN40 1HE

**Trustees**

Professor T P Hughes Professor  
Professor M Baccarani Professor (resigned 20/12/2021)  
Professor J Cortes Professor  
Professor B Druker Professor  
Professor A Hochhaus Professor  
Professor J Radich Professor  
Professor C Schiffer Professor  
Professor J F Apperley DM FRCP/Path Professor  
Professor M Mauro Professor  
Professor G Saglio Professor

**Company Secretary**

Ms N C Evans

**REPORT OF THE TRUSTEES  
FOR THE YEAR ENDED 31ST AUGUST 2021**

---

**REFERENCE AND ADMINISTRATIVE DETAILS**

**Independent Examiner**

R Appleyard FCA

ICAEW

Gibbons Mannington & Phipps LLP

Chartered Accountants

20 Eversley Road

Bexhill-on-Sea

East Sussex

TN40 1HE

**Bankers**

HSBC Bank, 152 Portobello Road, London, W11 2EA

This report has been prepared in accordance with the special provisions of Part 15 of the Companies Act 2006 relating to small companies.

Approved by order of the board of trustees on 27th May 2022 and signed on its behalf by:

Professor T P Hughes - Trustee

**Independent examiner's report to the trustees of The International CML Foundation ('the Company')**

I report to the charity trustees on my examination of the accounts of the Company for the year ended 31st August 2021.

**Responsibilities and basis of report**

As the charity's trustees of the Company (and also its directors for the purposes of company law) you are responsible for the preparation of the accounts in accordance with the requirements of the Companies Act 2006 ('the 2006 Act').

Having satisfied myself that the accounts of the Company are not required to be audited under Part 16 of the 2006 Act and are eligible for independent examination, I report in respect of my examination of your charity's accounts as carried out under section 145 of the Charities Act 2011 ('the 2011 Act'). In carrying out my examination I have followed the Directions given by the Charity Commission under section 145(5) (b) of the 2011 Act.

**Independent examiner's statement - matters of concern identified**

I have completed my examination.

I draw attention to Note 10 of the accounts, regarding the balance of funds held by Paypal. Whilst nothing has come to my attention to indicate that the balance shown in the accounts is incorrect, it has not been possible to verify the balance of funds held in the Paypal account as part of my examination due to the fact that the charity is currently unable to access the account.

I confirm that no other matters have come to my attention in connection with the examination giving me reasonable cause to believe that in any material respect:

1. accounting records were not kept in respect of the Company as required by section 386 of the 2006 Act; or
2. the accounts do not accord with those records; or
3. the accounts do not comply with the accounting requirements of section 396 of the 2006 Act other than any requirement that the accounts give a true and fair view which is not a matter considered as part of an independent examination; and
4. the accounts have not been prepared in accordance with the methods and principles of the Statement of Recommended Practice for accounting and reporting by charities (applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102)).

I confirm that there are no other matters to which your attention should be drawn to enable a proper understanding of the accounts to be reached.

R Appleyard FCA  
ICAEW  
Gibbons Mannington & Phipps LLP  
Chartered Accountants  
20 Eversley Road  
Bexhill-on-Sea  
East Sussex  
TN40 1HE

30th May 2022

STATEMENT OF FINANCIAL ACTIVITIES  
FOR THE YEAR ENDED 31ST AUGUST 2021

	Notes	Unrestricted funds £	Restricted funds £	2021 Total funds £	2020 Total funds £
<b>INCOME AND ENDOWMENTS FROM</b>					
Donations and legacies		<b>8,459</b>	<b>66,648</b>	<b>75,107</b>	222,264
Other income	2	<b>(5,904)</b>	-	<b>(5,904)</b>	(21,893)
<b>Total</b>		<b>2,555</b>	<b>66,648</b>	<b>69,203</b>	200,371
<b>EXPENDITURE ON</b>					
<b>Charitable activities</b>					
Preceptorships		-	-	-	36,692
Diagnosis & testing		-	-	-	1,035
Virtual Education Program		-	-	-	30,598
Scientific meetings		<b>696</b>	-	<b>696</b>	14,143
ICMLF Forum		<b>3,402</b>	-	<b>3,402</b>	30,370
Communications		<b>1,414</b>	<b>27,617</b>	<b>29,031</b>	31,936
Fundraising		<b>5,818</b>	<b>3,095</b>	<b>8,913</b>	21,481
Cure Consortium		-	<b>5,147</b>	<b>5,147</b>	5,316
Candid		<b>39</b>	<b>35,074</b>	<b>35,113</b>	35,998
Knowledge Centre		<b>21,529</b>	-	<b>21,529</b>	-
Conversations		<b>27,098</b>	<b>1,840</b>	<b>28,938</b>	-
Other		<b>13,891</b>	-	<b>13,891</b>	19,718
<b>Total</b>		<b>73,887</b>	<b>72,773</b>	<b>146,660</b>	227,287
<b>NET INCOME/(EXPENDITURE)</b>		<b>(71,332)</b>	<b>(6,125)</b>	<b>(77,457)</b>	(26,916)
<b>RECONCILIATION OF FUNDS</b>					
<b>Total funds brought forward</b>		<b>228,033</b>	<b>154,771</b>	<b>382,804</b>	409,720
<b>TOTAL FUNDS CARRIED FORWARD</b>		<b>156,701</b>	<b>148,646</b>	<b>305,347</b>	382,804

The notes form part of these financial statements

**BALANCE SHEET  
31ST AUGUST 2021**

	Notes	Unrestricted funds £	Restricted funds £	<b>2021 Total funds £</b>	2020 Total funds £
<b>CURRENT ASSETS</b>					
Debtors	10	<b>86,793</b>	-	<b>86,793</b>	92,949
Cash at bank and in hand		<b>74,181</b>	<b>148,645</b>	<b>222,826</b>	294,025
		<b>160,974</b>	<b>148,645</b>	<b>309,619</b>	386,974
<b>CREDITORS</b>					
Amounts falling due within one year	11	<b>(4,272)</b>	-	<b>(4,272)</b>	(4,170)
<b>NET CURRENT ASSETS</b>		<b>156,702</b>	<b>148,645</b>	<b>305,347</b>	382,804
<b>TOTAL ASSETS LESS CURRENT LIABILITIES</b>		<b>156,702</b>	<b>148,645</b>	<b>305,347</b>	382,804
<b>NET ASSETS</b>		<b>156,702</b>	<b>148,645</b>	<b>305,347</b>	382,804
<b>FUNDS</b>					
Unrestricted funds	12			<b>156,702</b>	228,033
Restricted funds				<b>148,645</b>	154,771
<b>TOTAL FUNDS</b>				<b>305,347</b>	382,804

The charitable company is entitled to exemption from audit under Section 477 of the Companies Act 2006 for the year ended 31st August 2021.

The members have not required the company to obtain an audit of its financial statements for the year ended 31st August 2021 in accordance with Section 476 of the Companies Act 2006.

The trustees acknowledge their responsibilities for

- ensuring that the charitable company keeps accounting records that comply with Sections 386 and 387 of the Companies Act 2006 and
- preparing financial statements which give a true and fair view of the state of affairs of the charitable company as at the end of each financial year and of its surplus or deficit for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the charitable company.

These financial statements have been prepared in accordance with the provisions applicable to charitable companies subject to the small companies regime.

The financial statements were approved by the Board of Trustees and authorised for issue on 27th May 2022 and were signed on its behalf by:

T P Hughes - Trustee

The notes form part of these financial statements

**NOTES TO THE FINANCIAL STATEMENTS  
FOR THE YEAR ENDED 31ST AUGUST 2021**

---

**1. ACCOUNTING POLICIES****Basis of preparing the financial statements**

The financial statements of the charitable company, which is a public benefit entity under FRS 102, have been prepared in accordance with the Charities SORP (FRS 102) 'Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2019)', Financial Reporting Standard 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland' and the Companies Act 2006. The financial statements have been prepared under the historical cost convention.

**Income**

Items of income are recognised and included in the accounts when all of the following criteria are met:

- The charity or its subsidiary have entitlement to the funds;
- any performance conditions attached to the item(s) of income have been met or are fully within the control of the charity or its subsidiary;
- there is sufficient certainty that receipt of the income is considered probable; and
- the amount can be measured reliably.

**Expenditure**

Liabilities are recognised as expenditure as soon as there is a legal or constructive obligation committing the charity to that expenditure, it is probable that a transfer of economic benefits will be required in settlement and the amount of the obligation can be measured reliably. Expenditure is accounted for on an accruals basis and has been classified under headings that aggregate all cost related to the category. Where costs cannot be directly attributed to particular headings they have been allocated to activities on a basis consistent with the use of resources.

Grants offered subject to conditions which have not been met at the year end date are noted as a commitment but not accrued as expenditure.

**Debtors**

Debtors are recognised at the settlement amount due after any trade discount offered. Prepayments are valued at the amount prepaid after taking account of any trade discounts due.

**Creditors and provisions**

Creditors and provisions are recognised where the charity has a present obligation resulting from a past event that will probably result in the transfer of funds to a third party and the amount due to settle the obligation can be measured or estimated reliably. Creditors and provisions are normally recognised at their settlement amount after allowing for any trade discounts due.

**Taxation**

The charity is exempt from corporation tax on its charitable activities.

**Fund accounting**

Unrestricted funds can be used in accordance with the charitable objectives at the discretion of the trustees.

Restricted funds can only be used for particular restricted purposes within the objects of the charity. Restrictions arise when specified by the donor or when funds are raised for particular restricted purposes.

Further explanation of the nature and purpose of each fund is included in the notes to the financial statements.

NOTES TO THE FINANCIAL STATEMENTS - continued  
FOR THE YEAR ENDED 31ST AUGUST 2021**1. ACCOUNTING POLICIES - continued****Foreign currencies**

Assets and liabilities in foreign currencies are translated into sterling at the rates of exchange ruling at the balance sheet date. Transactions in foreign currencies are translated into sterling at the rate of exchange ruling at the date of transaction. Exchange differences are taken into account in arriving at the operating result and are shown as other income.

**2. OTHER INCOME**

Other income consists of the profit on foreign currency exchange in accordance with the accounting policy on foreign exchange transactions.

**3. GRANTS PAYABLE**

	<b>2021</b>	2020
	£	£
Preceptorships	-	23,963
Diagnosis & testing	-	1,035
	<u>-</u>	<u>24,998</u>

**4. SUPPORT COSTS**

	Management fees £	Finance £	Other £	Governance costs £	Totals £
Other resources expended	<b>10,865</b>	<b>395</b>	<b>2,631</b>	-	<b>13,891</b>
ICMLF Forum	<b>3,402</b>	-	-	-	<b>3,402</b>
Communications	<b>25,822</b>	-	-	<b>1,414</b>	<b>27,236</b>
Fundraising	<b>8,506</b>	-	-	-	<b>8,506</b>
Cure Consortium	<b>5,103</b>	-	-	-	<b>5,103</b>
Candid	<b>34,197</b>	-	-	-	<b>34,197</b>
Knowledge Centre	<b>19,298</b>	-	-	<b>1,414</b>	<b>20,712</b>
Conversations	<b>25,720</b>	-	-	<b>1,414</b>	<b>27,134</b>
	<u><b>132,913</b></u>	<u><b>395</b></u>	<u><b>2,631</b></u>	<u><b>4,242</b></u>	<u><b>140,181</b></u>

Support costs, included in the above, are as follows:

**Management fees**

	Other resources expended £	ICMLF Forum £	Communications £	Fundraising £	Cure Consortium £
Management & admin	<u><b>10,865</b></u>	<u><b>3,402</b></u>	<u><b>25,822</b></u>	<u><b>8,506</b></u>	<u><b>5,103</b></u>

NOTES TO THE FINANCIAL STATEMENTS - continued  
FOR THE YEAR ENDED 31ST AUGUST 2021

## 4. SUPPORT COSTS - continued

## Management fees - continued

	Candid £	Knowledge Centre £	Conversations £	2021 Total activities £	2020 Total activities £
Management & admin	<u>34,197</u>	<u>19,298</u>	<u>25,720</u>	<u>132,913</u>	<u>137,412</u>

## Finance

	2021 Other resources expended £	2020 Total activities £
Bank charges	<u>395</u>	<u>1,536</u>

## Other

	2021 Other resources expended £	2020 Total activities £
Sundry office costs	<u>2,631</u>	<u>1,930</u>

## Governance costs

	Communications £	Knowledge Centre £	Conversations £	2021 Total activities £	2020 Total activities £
Accountancy - Independent examination fee	<u>1,414</u>	<u>1,414</u>	<u>1,414</u>	<u>4,242</u>	<u>4,260</u>

## 5. NET INCOME/(EXPENDITURE)

Net income/(expenditure) is stated after charging/(crediting):

	2021 £	2020 £
Accountancy - Independent examination fee	<u>4,242</u>	<u>4,260</u>

## 6. TRUSTEES' REMUNERATION AND BENEFITS

There were no trustees' remuneration or other benefits for the year ended 31st August 2021 nor for the year ended 31st August 2020.

## Trustees' expenses

There were no trustees' expenses paid for the year ended 31st August 2021 nor for the year ended 31st August 2020.

NOTES TO THE FINANCIAL STATEMENTS - continued  
FOR THE YEAR ENDED 31ST AUGUST 2021**7. STAFF COSTS**

The average monthly number of employees during the year was as follows:

	<b>2021</b>	2020
Charitable activities	<b>4</b>	3
	<u>4</u>	<u>3</u>

The number of employees whose employee benefits (excluding employer pension costs) exceeded £60,000 was:

	<b>2021</b>	2020
£80,001 - £90,000	<b>1</b>	-
£90,001 - £100,000	-	1
	<u>1</u>	<u>1</u>

**8. COMPARATIVES FOR THE STATEMENT OF FINANCIAL ACTIVITIES**

	Unrestricted funds £	Restricted funds £	Total funds £
<b>INCOME AND ENDOWMENTS FROM</b>			
Donations and legacies	65,872	156,392	222,264
Other income	(21,893)	-	(21,893)
<b>Total</b>	<u>43,979</u>	<u>156,392</u>	<u>200,371</u>
<b>EXPENDITURE ON</b>			
<b>Charitable activities</b>			
Preceptorships	532	36,160	36,692
Diagnosis & testing	-	1,035	1,035
Virtual Education Program	531	30,067	30,598
Scientific meetings	9,183	4,960	14,143
ICMLF Forum	30,370	-	30,370
Communications	533	31,403	31,936
Fundraising	533	20,948	21,481
Cure Consortium	533	4,783	5,316
Candid	35,998	-	35,998
Other	19,718	-	19,718
<b>Total</b>	<u>97,931</u>	<u>129,356</u>	<u>227,287</u>
<b>NET INCOME/(EXPENDITURE)</b>	<u>(53,952)</u>	<u>27,036</u>	<u>(26,916)</u>
<b>RECONCILIATION OF FUNDS</b>			
<b>Total funds brought forward</b>	281,986	127,734	409,720
<b>TOTAL FUNDS CARRIED FORWARD</b>	<u>228,034</u>	<u>154,770</u>	<u>382,804</u>

NOTES TO THE FINANCIAL STATEMENTS - continued  
FOR THE YEAR ENDED 31ST AUGUST 2021**9. VOLUNTEERS**

The charity heavily relies upon the many medical professionals who donate their time to help run the various charitable activities undertaken. It is not possible to accurately calculate the value of the services contributed by these volunteers and therefore the numbers do not reflect either the income or expenditure, however it is thought to be in the region of £230,000.

**10. DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR**

	<b>2021</b>	2020
	<b>£</b>	£
Other debtors	<b><u>86,793</u></b>	<u>92,949</u>

Included within other debtors is a balance of £84,202 in respect of funds held by Paypal. As a result of a change of personnel, the account access is being transferred by Paypal, and until this process has been completed the charity cannot transfer or use these funds.

**11. CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR**

	<b>2021</b>	2020
	<b>£</b>	£
Accrued expenses	<b><u>4,272</u></b>	<u>4,170</u>

**12. MOVEMENT IN FUNDS**

	At 1/9/20	Net movement in funds	At
	£	£	31/8/21 £
<b>Unrestricted funds</b>			
General fund	<b>224,118</b>	<b>(67,416)</b>	<b>156,702</b>
Cepheid	<b>3,915</b>	<b>(3,915)</b>	-
	<b><u>228,033</u></b>	<b><u>(71,331)</u></b>	<b><u>156,702</u></b>
<b>Restricted funds</b>			
Novartis Pharmaceuticals Corporation	<b>123,410</b>	-	<b>123,410</b>
Pfizer	<b>23,118</b>	<b>1,745</b>	<b>24,863</b>
Novartis Killi Climb	<b>8,243</b>	<b>(8,243)</b>	-
Novartis Patient	-	<b>372</b>	<b>372</b>
	<b><u>154,771</u></b>	<b><u>(6,126)</u></b>	<b><u>148,645</u></b>
<b>TOTAL FUNDS</b>	<b><u>382,804</u></b>	<b><u>(77,457)</u></b>	<b><u>305,347</u></b>

NOTES TO THE FINANCIAL STATEMENTS - continued  
FOR THE YEAR ENDED 31ST AUGUST 2021**12. MOVEMENT IN FUNDS - continued**

Net movement in funds, included in the above are as follows:

	Incoming resources £	Resources expended £	Movement in funds £
<b>Unrestricted funds</b>			
General fund	2,555	(69,971)	(67,416)
Cepheid	-	(3,915)	(3,915)
	<u>2,555</u>	<u>(73,886)</u>	<u>(71,331)</u>
<b>Restricted funds</b>			
Takeda Oncology	29,457	(29,457)	-
Pfizer	36,819	(35,074)	1,745
Novartis Killi Climb	-	(8,243)	(8,243)
Novartis Patient	372	-	372
	<u>66,648</u>	<u>(72,774)</u>	<u>(6,126)</u>
<b>TOTAL FUNDS</b>	<u>69,203</u>	<u>(146,660)</u>	<u>(77,457)</u>

**Comparatives for movement in funds**

	At 1/9/19 £	Net movement in funds £	At 31/8/20 £
<b>Unrestricted funds</b>			
General fund	281,986	(57,868)	224,118
Cepheid	-	3,915	3,915
	<u>281,986</u>	<u>(53,953)</u>	<u>228,033</u>
<b>Restricted funds</b>			
Bristol-Myers Squibb	680	(680)	-
Novartis Pharmaceuticals Corporation	124,445	(1,035)	123,410
Takeda Oncology	2,609	(2,609)	-
Pfizer	-	23,118	23,118
Novartis Killi Climb	-	8,243	8,243
	<u>127,734</u>	<u>27,037</u>	<u>154,771</u>
<b>TOTAL FUNDS</b>	<u>409,720</u>	<u>(26,916)</u>	<u>382,804</u>

NOTES TO THE FINANCIAL STATEMENTS - continued  
FOR THE YEAR ENDED 31ST AUGUST 2021

## 12. MOVEMENT IN FUNDS - continued

Comparative net movement in funds, included in the above are as follows:

	Incoming resources £	Resources expended £	Movement in funds £
<b>Unrestricted funds</b>			
General fund	40,064	(97,932)	(57,868)
Cepheid	3,915	-	3,915
	<u>43,979</u>	<u>(97,932)</u>	<u>(53,953)</u>
<b>Restricted funds</b>			
Bristol-Myers Squibb	-	(680)	(680)
Novartis Pharmaceuticals Corporation	-	(1,035)	(1,035)
Takeda Oncology	-	(2,609)	(2,609)
Pfizer	117,458	(94,340)	23,118
Novartis Killi Climb	26,144	(17,901)	8,243
Novartis Colt	4,960	(4,960)	-
Bristol-Myers Squibb	7,830	(7,830)	-
	<u>156,392</u>	<u>(129,355)</u>	<u>27,037</u>
<b>TOTAL FUNDS</b>	<u>200,371</u>	<u>(227,287)</u>	<u>(26,916)</u>

A current year 12 months and prior year 12 months combined position is as follows:

	At 1/9/19 £	Net movement in funds £	At 31/8/21 £
<b>Unrestricted funds</b>			
General fund	281,986	(125,284)	156,702
<b>Restricted funds</b>			
Bristol-Myers Squibb	680	(680)	-
Novartis Pharmaceuticals Corporation	124,445	(1,035)	123,410
Takeda Oncology	2,609	(2,609)	-
Pfizer	-	24,863	24,863
Novartis Patient	-	372	372
	<u>127,734</u>	<u>20,911</u>	<u>148,645</u>
<b>TOTAL FUNDS</b>	<u>409,720</u>	<u>(104,373)</u>	<u>305,347</u>

NOTES TO THE FINANCIAL STATEMENTS - continued  
FOR THE YEAR ENDED 31ST AUGUST 2021**12. MOVEMENT IN FUNDS - continued**

A current year 12 months and prior year 12 months combined net movement in funds, included in the above are as follows:

	Incoming resources £	Resources expended £	Movement in funds £
<b>Unrestricted funds</b>			
General fund	42,619	(167,903)	(125,284)
Cepheid	3,915	(3,915)	-
	<u>46,534</u>	<u>(171,818)</u>	<u>(125,284)</u>
<b>Restricted funds</b>			
Bristol-Myers Squibb	-	(680)	(680)
Novartis Pharmaceuticals Corporation	-	(1,035)	(1,035)
Takeda Oncology	29,457	(32,066)	(2,609)
Pfizer	154,277	(129,414)	24,863
Novartis Killi Climb	26,144	(26,144)	-
Novartis Colt	4,960	(4,960)	-
Bristol-Myers Squibb	7,830	(7,830)	-
Novartis Patient	372	-	372
	<u>223,040</u>	<u>(202,129)</u>	<u>20,911</u>
<b>TOTAL FUNDS</b>	<u>269,574</u>	<u>(373,947)</u>	<u>(104,373)</u>

**13. RELATED PARTY DISCLOSURES**

There were no related party transactions for the year ended 31st August 2021.

**THE INTERNATIONAL CML FOUNDATION**

England & Wales - Charity number 1132984

---

# Accounts

---

**REGISTERED COMPANY NUMBER: 06996068 (England and Wales)**  
**REGISTERED CHARITY NUMBER: 1132984**

**REPORT OF THE TRUSTEES AND  
UNAUDITED FINANCIAL STATEMENTS  
FOR THE YEAR ENDED 31ST AUGUST 2020  
FOR  
THE INTERNATIONAL CML FOUNDATION**

Gibbons Mannington & Phipps LLP  
Chartered Accountants  
20 Eversley Road  
Bexhill-on-Sea  
East Sussex  
TN40 1HE

**THE INTERNATIONAL CML FOUNDATION**  
**CONTENTS OF THE FINANCIAL STATEMENTS**  
**FOR THE YEAR ENDED 31ST AUGUST 2020**

---

	<b>Page</b>
<b>Report of the Trustees</b>	1 to 5
<b>Independent Examiner's Report</b>	6
<b>Statement of Financial Activities</b>	7
<b>Balance Sheet</b>	8
<b>Notes to the Financial Statements</b>	9 to 17

---

## **THE INTERNATIONAL CML FOUNDATION (REGISTERED NUMBER: 06996068)**

### **REPORT OF THE TRUSTEES FOR THE YEAR ENDED 31ST AUGUST 2020**

---

The trustees who are also directors of the charity for the purposes of the Companies Act 2006, present their report with the financial statements of the charity for the year ended 31st August 2020. The trustees have adopted the provisions of Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2019).

#### **OBJECTIVES AND ACTIVITIES**

##### **Objectives and aims**

The object of the Foundation is the advancement of health by the improvement of the treatment in all parts of the world of chronic myeloid leukaemia and related diseases (together "CML") and for the purpose of carrying out those general objects, the primary objects of the Foundation are in particular:-

- (i) to improve clinical practice and disease monitoring in the treatment of CML
- (ii) to support, encourage and promote research into the causes, prevention, study and treatment of CML
- (iii) to promote and support the education of and disseminate knowledge amongst clinicians, scientists, health professionals and patients in matters concerning CML
- (iv) to promote, foster and co-ordinate collaboration that is particularly (but not exclusively) international and is not only in the areas and activities of clinical practice disease monitoring and research into CML but also in any area or activity which is or may be conducive to the acceleration of the control and/or cure of CML
- (v) to promote, set up, establish and support and share and exchange knowledge with other organisations whose objects are similar to these general or primary objects
- (vi) to assist or promote any other charitable purposes which are related to these general and primary objects.

##### **Significant activities**

In furtherance of the objects, the Foundation has the following powers:-

- (i) to promote or carry out research
- (ii) to provide advice
- (iii) to give and exchange information and advice and promote learning, study and research
- (iv) to commission, publish, distribute and contribute to papers, books, periodicals, reports, leaflets, posters and other publications of any description
- (v) to hold, attend and sponsor conferences, meetings, lectures, exhibitions and discussions
- (vi) to raise funds and to apply for and solicit grants from pharmaceutical companies anywhere in the world.

##### **Public benefit**

The Trustees have considered their duty to have due regard to public benefit guidance published by the Commission and in their opinion, the foregoing report on the achievements and performance demonstrates that they have complied therewith.

**REPORT OF THE TRUSTEES  
FOR THE YEAR ENDED 31ST AUGUST 2020**

---

**ACHIEVEMENT AND PERFORMANCE**

**Charitable activities**

The 2019/2020-year for the iCMLf can clearly be separated into pre and post pandemic activities. September to December 2019 saw the conclusion of the fundraising activity where 26 members of the iCMLf climbed Mount Kilimanjaro and raised over \$300,000 for the iCMLf cure programs. While in Africa we hosted the first iCMLf education symposium on the continent, which was closely followed by the iCMLf Forum for physicians from emerging regions in the USA. 10 physicians finalized their preceptorships and 20 more were accepted into the 2020 program.

In February 2020 it became clear that the pandemic was going to fundamentally change the activities, programs and funding of the Foundation. We halted all travel for the preceptors and the program is on hiatus for the foreseeable future.

Given lack of knowledge and concern for patient's vulnerability, the experts treating CML started to share experiences and ideas. This international collaboration began organically and it quickly became clear that the iCMLf was ideally positioned to coordinate this effort. As case collection expanded and formalised, we formed the iCMLf CANDID (Cml AND covid) study. The primary aim of this study is to collect emerging clinical data on CML patients infected with the SARS-CoV-2 virus as rapidly as possible. To date 202 cases have been collected and an abstract accepted for presentation at the American Society of Hematology meeting in December 2020.

As information changed and the pandemic worsened the Foundation initiated key activities to provide guidance and reassurance to both physicians and their CML patients alike. The online COVID-19 hub hosts expert statements, frequently asked questions, relevant clinical papers and other reliable resources. Launched in April 2020 the Hub has had 28,000 views to the 31st August.

The iCMLf hosted live webinars with CML experts, on how to manage patients with CML during the COVID-19 pandemic. Commencing in May 2020, by 31st August 5 webinars had 400 participants and 1,300 views once available online.

**Online Education Services**

[WWW.CML-FOUNDATION.ORG](http://WWW.CML-FOUNDATION.ORG)

The iCMLf website has always been one of the key worldwide educational online resources for CML. In 2019/20 there were more than 25,000 visitors and 63,000 page visits. A 54% increase on 2018/2019.

Visitors were from 166 different countries and 71 % of these are low and middle-income countries.

Most visited pages focused on COVID-19 this year with the 3 highest viewed pages being; 1) Advice for people with CML and COVID-19, 2) Case Discussion Forum, 3) COVID-19 Hub.

**Virtual Education Programme**

19 new education modules were added in 2019/20.

There were 4,890 presentations viewed in the year. A 385 increase on 2018/19.

**Clinical Case Discussion Forum**

This saw more than 8,340 case views during 2019/20. A 15% increase on 2018/19

**COVID-19 Hub - New program April to August 2020**

Advice and information for people with CML and COVID-19 with 28,000 views to date.

**iCMLf Conversations - New program May to August 2020**

The iCMLf hosted 5 live webinars with CML experts. Over 400 participants and more than 1,300 views on-demand to date.

## **THE INTERNATIONAL CML FOUNDATION (REGISTERED NUMBER: 06996068)**

### **REPORT OF THE TRUSTEES FOR THE YEAR ENDED 31ST AUGUST 2020**

---

#### **Preceptorships**

The iCMLf Clinical Preceptorship Program continues to improve the knowledge and skills of physicians treating CML in emerging economic regions through individually tailored observerships. During their 3-4 week intensive program, participants are involved in outpatient clinics, haematology ward rounds, seminars, discussion forums and laboratory work to arm them with a practical understanding of the most up-to-date protocols and guidelines to treat CML. One of the most valued benefits continues to be the close contacts and networks established during their time at the centre which continue to support their needs even after they have returned home.

From 1st September 2019 to 31st December 2019 10 physicians from emerging regions took part in the program. In January 2020 a further 20 preceptors were accepted into the program with 11 confirmed dates and 2 incurring travel costs.

#### **Fundraising activities**

The fundraising activity is a large component of the Chief Executive's travel to the scientific meetings as these are where future funding with potential donors is discussed.

In 2019/2020 our major public fundraising activity was preparation for the iCMLf climb for a cure in October 2019. A team of 26 people climbed Mount Kilimanjaro and raised \$305,000 in total (2018-2020)

Funds raised in 2019 from the annual John Goldman Fun Run also supported the iCMLf Climb for a Cure.

#### **FINANCIAL REVIEW**

##### **Financial position**

The financial position of the International CML Foundation remains solid.

##### **Principal funding sources**

The iCMLf works closely with industry and community partners to secure unrestricted grants and sponsorship for our programs and activities. The iCMLf requests donations through the iCMLf website. In 2019/2020 funds were raised through the fundraising adventure the iCMLf Climb for a Cure and on the annual John Goldman Fun Run.

##### **Reserves policy**

The reserves at the year end were £383,014 (2019 - £409,720). It is the policy of the Trustees to maintain sufficient reserves to ensure the day to day running of the Foundation. The level of reserves and current financial commitments are reviewed regularly at Trustees' meetings. The Foundation plans to hold a minimum of £150,000 as reserve funding. This is the amount for the foundation to operate without further income/outgoings for one year.

#### **FUTURE PLANS**

While maintaining the expert best practice and education initiatives of the Foundation, we aim to harness global network of the iCMLf to enhance research into potential cures for CML. The iCMLf Genomics Alliance will access the wealth of genomic information that is generated in local CML research projects by facilitating data assimilation and samples exchanges through an international data collection platform. Combining many data sets and facilitating global collaborative studies will enable us to develop a baseline predictor of adverse outcomes.

The iCMLf TFR Alliance looks to define biomarkers for treatment discontinuation and a functional cure of CML.

The CML and COVID-19 retrospective case analysis will provide data for physicians to base treatment decisions on as the pandemic continues and vaccines become available.

#### **STRUCTURE, GOVERNANCE AND MANAGEMENT**

##### **Governing document**

The charity is controlled by its governing document, a deed of trust, and constitutes a limited company, limited by guarantee, as defined by the Companies Act 2006.

**REPORT OF THE TRUSTEES  
FOR THE YEAR ENDED 31ST AUGUST 2020**

---

**STRUCTURE, GOVERNANCE AND MANAGEMENT**

**Recruitment and appointment of new trustees**

The power of appointing new or additional Trustees is vested in the existing Trustees. Prior to appointment, new Trustees would be introduced to the workings of the Foundation and advised of their responsibilities.

**Organisational structure**

The chief executive reports to the ten iCMLf Directors, specifically the iCMLf Chairman.

The operational team; Communications Director, Digital Media Officer, and ERSAP Program Coordinator, report to the chief executive.

Strategic direction, financial review and budget approval are set at an annual iCMLf directors meeting in September each year. Further directors planning and discussion meetings are held quarterly.

Strategic planning is assisted with an annual advisors meeting. This includes the thirteen physicians, scientific and patient advisors and members from the 36 countries with iCMLf National Representatives.

The operational team meets every 6-8 weeks. The editor and chief executive meet biweekly and the program coordinator and chief executive meet weekly for business planning. The chief executive and iCMLf Chairman meet monthly.

Decisions are escalated from the operational team to the chief executive, iCMLf Chairman and iCMLf Board of Directors according to scale and impact.

**REFERENCE AND ADMINISTRATIVE DETAILS**

**Registered Company number**

06996068 (England and Wales)

**Registered Charity number**

1132984

**Registered office**

20 Eversley Road  
Bexhill-on-Sea  
East Sussex  
TN40 1HE

**Trustees**

Professor T P Hughes Professor  
Professor M Baccarani Professor  
Professor J Cortes Professor  
Professor B Druker Professor  
Professor A Hochhaus Professor  
Professor J Radich Professor  
Professor C Schiffer Professor  
Professor J F Apperley DM FRCP/Path Professor  
Professor M Mauro Professor  
Professor G Saglio Professor

**Company Secretary**

Ms N C Evans

**REPORT OF THE TRUSTEES  
FOR THE YEAR ENDED 31ST AUGUST 2020**

---

**REFERENCE AND ADMINISTRATIVE DETAILS**

**Independent Examiner**


R Appleyard FCA  
ICAEW  
Gibbons Mannington & Phipps LLP  
Chartered Accountants  
20 Eversley Road  
Bexhill-on-Sea  
East Sussex  
TN40 1HE

**Bankers**

HSBC Bank, 152 Portobello Road, London, W11 2EA

This report has been prepared in accordance with the special provisions of Part 15 of the Companies Act 2006 relating to small companies.

Approved by order of the board of trustees on 9th June 2021 and signed on its behalf by:



Professor T P Hughes - Trustee

**INDEPENDENT EXAMINER'S REPORT TO THE TRUSTEES OF  
THE INTERNATIONAL CML FOUNDATION (REGISTERED NUMBER: 06996068)**

---

**Independent examiner's report to the trustees of The International CML Foundation ('the Company')**

I report to the charity trustees on my examination of the accounts of the Company for the year ended 31st August 2020.

**Responsibilities and basis of report**

As the charity's trustees of the Company (and also its directors for the purposes of company law) you are responsible for the preparation of the accounts in accordance with the requirements of the Companies Act 2006 ('the 2006 Act').

Having satisfied myself that the accounts of the Company are not required to be audited under Part 16 of the 2006 Act and are eligible for independent examination, I report in respect of my examination of your charity's accounts as carried out under section 145 of the Charities Act 2011 ('the 2011 Act'). In carrying out my examination I have followed the Directions given by the Charity Commission under section 145(5) (b) of the 2011 Act.

**Independent examiner's statement**

I have completed my examination. I confirm that no matters have come to my attention in connection with the examination giving me cause to believe:

1. accounting records were not kept in respect of the Company as required by section 386 of the 2006 Act; or
2. the accounts do not accord with those records; or
3. the accounts do not comply with the accounting requirements of section 396 of the 2006 Act other than any requirement that the accounts give a true and fair view which is not a matter considered as part of an independent examination; or
4. the accounts have not been prepared in accordance with the methods and principles of the Statement of Recommended Practice for accounting and reporting by charities (applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102)).

I have no concerns and have come across no other matters in connection with the examination to which attention should be drawn in this report in order to enable a proper understanding of the accounts to be reached.

R Appleyard FCA  
ICAEW  
Gibbons Mannington & Phipps LLP  
Chartered Accountants  
20 Eversley Road  
Bexhill-on-Sea  
East Sussex  
TN40 1HE

15th June 2021

**THE INTERNATIONAL CML FOUNDATION**

**STATEMENT OF FINANCIAL ACTIVITIES  
FOR THE YEAR ENDED 31ST AUGUST 2020**

	Notes	Unrestricted funds £	Restricted funds £	<b>2020 Total funds £</b>	2019 Total funds £
<b>INCOME AND ENDOWMENTS FROM</b>					
Donations and legacies		<b>65,872</b>	<b>156,392</b>	<b>222,264</b>	376,919
Other income	2	<b>(21,893)</b>	-	<b>(21,893)</b>	1,387
<b>Total</b>		<b>43,979</b>	<b>156,392</b>	<b>200,371</b>	378,306
<b>EXPENDITURE ON</b>					
<b>Charitable activities</b>					
Preceptorships		<b>532</b>	<b>36,160</b>	<b>36,692</b>	99,253
Diagnosis & testing		-	<b>1,035</b>	<b>1,035</b>	19,347
Virtual Education Program		<b>531</b>	<b>30,067</b>	<b>30,598</b>	52,117
Scientific meetings		<b>9,183</b>	<b>4,960</b>	<b>14,143</b>	17,000
ICMLF Forum		<b>30,370</b>	-	<b>30,370</b>	44,946
Clinical forum		-	-	-	2,192
Communications		<b>533</b>	<b>31,403</b>	<b>31,936</b>	29,719
Fundraising		<b>533</b>	<b>20,948</b>	<b>21,481</b>	34,184
Cure C		<b>533</b>	<b>4,783</b>	<b>5,316</b>	6,355
Candid		<b>35,998</b>	-	<b>35,998</b>	-
Other		<b>19,718</b>	-	<b>19,718</b>	18,781
<b>Total</b>		<b>97,931</b>	<b>129,356</b>	<b>227,287</b>	323,894
<b>NET INCOME/(EXPENDITURE)</b>		<b>(53,952)</b>	<b>27,036</b>	<b>(26,916)</b>	54,412
<b>RECONCILIATION OF FUNDS</b>					
<b>Total funds brought forward</b>		<b>281,986</b>	<b>127,734</b>	<b>409,720</b>	355,308
<b>TOTAL FUNDS CARRIED FORWARD</b>		<b>228,034</b>	<b>154,770</b>	<b>382,804</b>	409,720

The notes form part of these financial statements

**THE INTERNATIONAL CML FOUNDATION (REGISTERED NUMBER: 06996068)**

**BALANCE SHEET  
31ST AUGUST 2020**

	Notes	Unrestricted funds £	Restricted funds £	<b>2020 Total funds £</b>	2019 Total funds £
<b>CURRENT ASSETS</b>					
Debtors	10	<b>92,949</b>	-	<b>92,949</b>	52,214
Cash at bank and in hand		<b>139,255</b>	<b>154,771</b>	<b>294,026</b>	361,466
		<b>232,204</b>	<b>154,771</b>	<b>386,975</b>	413,680
<b>CREDITORS</b>					
Amounts falling due within one year	11	<b>(4,171)</b>	-	<b>(4,171)</b>	(3,960)
<b>NET CURRENT ASSETS</b>		<b>228,033</b>	<b>154,771</b>	<b>382,804</b>	409,720
<b>TOTAL ASSETS LESS CURRENT LIABILITIES</b>		<b>228,033</b>	<b>154,771</b>	<b>382,804</b>	409,720
<b>NET ASSETS</b>		<b>228,033</b>	<b>154,771</b>	<b>382,804</b>	409,720
<b>FUNDS</b>					
	12				
Unrestricted funds				<b>228,033</b>	281,986
Restricted funds				<b>154,771</b>	127,734
<b>TOTAL FUNDS</b>				<b>382,804</b>	409,720

The charitable company is entitled to exemption from audit under Section 477 of the Companies Act 2006 for the year ended 31st August 2020.

The members have not required the company to obtain an audit of its financial statements for the year ended 31st August 2020 in accordance with Section 476 of the Companies Act 2006.

The trustees acknowledge their responsibilities for

- (a) ensuring that the charitable company keeps accounting records that comply with Sections 386 and 387 of the Companies Act 2006 and
- (b) preparing financial statements which give a true and fair view of the state of affairs of the charitable company as at the end of each financial year and of its surplus or deficit for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the charitable company.

These financial statements have been prepared in accordance with the provisions applicable to charitable companies subject to the small companies regime.

The financial statements were approved by the Board of Trustees and authorised for issue on 9th June 2021 and were signed on its behalf by:



T P Hughes - Trustee

**NOTES TO THE FINANCIAL STATEMENTS  
FOR THE YEAR ENDED 31ST AUGUST 2020**

---

**1. ACCOUNTING POLICIES**

**Basis of preparing the financial statements**

The financial statements of the charitable company, which is a public benefit entity under FRS 102, have been prepared in accordance with the Charities SORP (FRS 102) 'Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2019)', Financial Reporting Standard 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland' and the Companies Act 2006. The financial statements have been prepared under the historical cost convention.

**Income**

Items of income are recognised and included in the accounts when all of the following criteria are met:

- The charity or its subsidiary have entitlement to the funds;
- - any performance conditions attached to the item(s) of income have been met or are fully within the control of the charity or its subsidiary;
- there is sufficient certainty that receipt of the income is considered probable; and
  - the amount can be measured reliably.

**Expenditure**

Liabilities are recognised as expenditure as soon as there is a legal or constructive obligation committing the charity to that expenditure, it is probable that a transfer of economic benefits will be required in settlement and the amount of the obligation can be measured reliably. Expenditure is accounted for on an accruals basis and has been classified under headings that aggregate all cost related to the category. Where costs cannot be directly attributed to particular headings they have been allocated to activities on a basis consistent with the use of resources.

Grants offered subject to conditions which have not been met at the year end date are noted as a commitment but not accrued as expenditure.

**Debtors**

Debtors are recognised at the settlement amount due after any trade discount offered. Prepayments are valued at the amount prepaid after taking account of any trade discounts due.

**Creditors and provisions**

Creditors and provisions are recognised where the charity has a present obligation resulting from a past event that will probably result in the transfer of funds to a third party and the amount due to settle the obligation can be measured or estimated reliably. Creditors and provisions are normally recognised at their settlement amount after allowing for any trade discounts due.

**Taxation**

The charity is exempt from corporation tax on its charitable activities.

**Fund accounting**

Unrestricted funds can be used in accordance with the charitable objectives at the discretion of the trustees.

Restricted funds can only be used for particular restricted purposes within the objects of the charity. Restrictions arise when specified by the donor or when funds are raised for particular restricted purposes.

Further explanation of the nature and purpose of each fund is included in the notes to the financial statements.

**THE INTERNATIONAL CML FOUNDATION**

**NOTES TO THE FINANCIAL STATEMENTS - continued  
FOR THE YEAR ENDED 31ST AUGUST 2020**

**1. ACCOUNTING POLICIES - continued**

**Foreign currencies**

Assets and liabilities in foreign currencies are translated into sterling at the rates of exchange ruling at the balance sheet date. Transactions in foreign currencies are translated into sterling at the rate of exchange ruling at the date of transaction. Exchange differences are taken into account in arriving at the operating result and are shown as other income.

**2. OTHER INCOME**

Other income consists of the profit on foreign currency exchange in accordance with the accounting policy on foreign exchange transactions.

**3. GRANTS PAYABLE**

	<b>2020</b>	2019
	£	£
Preceptorships	<b>23,963</b>	76,623
Diagnosis & testing	<b>1,035</b>	9,457
	<u><b>24,998</b></u>	<u>86,080</u>

**4. SUPPORT COSTS**

	Management fees £	Finance £	Other £	Governance costs £	Totals £
Other resources expended	<b>16,252</b>	<b>1,536</b>	<b>1,930</b>	-	<b>19,718</b>
Preceptorships	<b>12,197</b>	-	-	<b>532</b>	<b>12,729</b>
Virtual Education Program	<b>28,198</b>	-	-	<b>532</b>	<b>28,730</b>
Scientific meetings	<b>3,611</b>	-	-	<b>532</b>	<b>4,143</b>
ICMLF Forum	<b>5,690</b>	-	-	<b>532</b>	<b>6,222</b>
Communications	<b>22,523</b>	-	-	<b>533</b>	<b>23,056</b>
Fundraising	<b>9,029</b>	-	-	<b>533</b>	<b>9,562</b>
Cure C	<b>4,514</b>	-	-	<b>533</b>	<b>5,047</b>
Candid	<b>35,398</b>	-	-	<b>533</b>	<b>35,931</b>
	<u><b>137,412</b></u>	<u><b>1,536</b></u>	<u><b>1,930</b></u>	<u><b>4,260</b></u>	<u><b>145,138</b></u>

**THE INTERNATIONAL CML FOUNDATION**

**NOTES TO THE FINANCIAL STATEMENTS - continued  
FOR THE YEAR ENDED 31ST AUGUST 2020**

**4. SUPPORT COSTS - continued**

Support costs, included in the above, are as follows:

**Management fees**

		Other resources expended £	Preceptorships £	Virtual Education Program £
Management & admin		<b>16,252</b>	<b>12,197</b>	<b>28,198</b>
	Scientific meetings	ICMLF Forum	Communications	Fundraising
	£	£	£	£
Management & admin	<b>3,611</b>	<b>5,690</b>	<b>22,523</b>	<b>9,029</b>
	Cure C £	Candid £	2020 Total activities £	2019 Total activities £
Management & admin	<b>4,514</b>	<b>35,398</b>	<b>137,412</b>	<b>125,954</b>
			2020 Other resources expended £	2019 Total activities £
Bank charges			<b>1,536</b>	<b>1,841</b>
			2020 Other resources expended £	2019 Total activities £
Sundry office costs			<b>1,930</b>	<b>1,809</b>
	Preceptorships	Virtual Education Program	Scientific meetings	ICMLF Forum
	£	£	£	£
Accountancy - Independent examination fee	<b>532</b>	<b>532</b>	<b>532</b>	<b>533</b>

## THE INTERNATIONAL CML FOUNDATION

### NOTES TO THE FINANCIAL STATEMENTS - continued FOR THE YEAR ENDED 31ST AUGUST 2020

#### 4. SUPPORT COSTS - continued

##### Governance costs - continued

	Fundraising £	Cure C £	Candid £	2020 Total activities £	2019 Total activities £
Accountancy - Independent examination fee	<u>533</u>	<u>533</u>	<u>533</u>	<u>4,260</u>	<u>4,320</u>

#### 5. NET INCOME/(EXPENDITURE)

Net income/(expenditure) is stated after charging/(crediting):

	2020 £	2019 £
Accountancy - Independent examination fee	<u>4,260</u>	<u>4,320</u>

#### 6. TRUSTEES' REMUNERATION AND BENEFITS

There were no trustees' remuneration or other benefits for the year ended 31st August 2020 nor for the year ended 31st August 2019.

##### Trustees' expenses

There were no trustees' expenses paid for the year ended 31st August 2020 nor for the year ended 31st August 2019.

#### 7. STAFF COSTS

The average monthly number of employees during the year was as follows:

	2020	2019
Charitable activities	<u>3</u>	<u>3</u>

The number of employees whose employee benefits (excluding employer pension costs) exceeded £60,000 was:

	2020	2019
£80,001 - £90,000	-	1
£90,001 - £100,000	<u>1</u>	-
	<u>1</u>	<u>1</u>

**THE INTERNATIONAL CML FOUNDATION****NOTES TO THE FINANCIAL STATEMENTS - continued  
FOR THE YEAR ENDED 31ST AUGUST 2020****8. COMPARATIVES FOR THE STATEMENT OF FINANCIAL ACTIVITIES**

	Unrestricted funds £	Restricted funds £	Total funds £
<b>INCOME AND ENDOWMENTS FROM</b>			
Donations and legacies	144,635	232,284	376,919
Other income	1,387	-	1,387
<b>Total</b>	<b>146,022</b>	<b>232,284</b>	<b>378,306</b>
<b>EXPENDITURE ON</b>			
<b>Charitable activities</b>			
Preceptorships	99,253	-	99,253
Diagnosis & testing	480	18,867	19,347
Virtual Education Program	6,464	45,653	52,117
Scientific meetings	17,000	-	17,000
ICMLF Forum	34,155	10,791	44,946
Clinical forum	2,192	-	2,192
Communications	480	29,239	29,719
Fundraising	34,184	-	34,184
Cure C	6,355	-	6,355
Other	18,781	-	18,781
<b>Total</b>	<b>219,344</b>	<b>104,550</b>	<b>323,894</b>
<b>NET INCOME/(EXPENDITURE)</b>	<b>(73,322)</b>	<b>127,734</b>	<b>54,412</b>
<b>RECONCILIATION OF FUNDS</b>			
<b>Total funds brought forward</b>	<b>355,308</b>	<b>-</b>	<b>355,308</b>
<b>TOTAL FUNDS CARRIED FORWARD</b>	<b>281,986</b>	<b>127,734</b>	<b>409,720</b>

**9. VOLUNTEERS**

The charity heavily relies upon the many medical professionals who donate their time to help run the various charitable activities undertaken. It is not possible to accurately calculate the value of the services contributed by these volunteers and therefore the numbers do not reflect either the income or expenditure, however it is thought to be in the region of £230,000.

**THE INTERNATIONAL CML FOUNDATION**

**NOTES TO THE FINANCIAL STATEMENTS - continued  
FOR THE YEAR ENDED 31ST AUGUST 2020**

**10. DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR**

	<b>2020</b>	2019
	<b>£</b>	£
Other debtors	<b><u>92,949</u></b>	<u>52,214</u>

Included within other debtors is a balance of £84,202 in respect of funds held by Paypal. As a result of a change of personnel, the account access is being transferred by Paypal, and until this process has been completed the charity cannot transfer or use these funds.

**11. CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR**

	<b>2020</b>	2019
	<b>£</b>	£
Accrued expenses	<b><u>4,171</u></b>	<u>3,960</u>

**12. MOVEMENT IN FUNDS**

	At 1/9/19	Net movement in funds	At 31/8/20
	£	£	£
<b>Unrestricted funds</b>			
General fund	<b>281,986</b>	<b>(57,868)</b>	<b>224,118</b>
Cepheid	-	<b>3,915</b>	<b>3,915</b>
	<b><u>281,986</u></b>	<b><u>(53,953)</u></b>	<b><u>228,033</u></b>
<b>Restricted funds</b>			
Bristol-Myers Squibb	<b>680</b>	<b>(680)</b>	-
Novartis Pharmaceuticals Corporation	<b>124,445</b>	<b>(1,035)</b>	<b>123,410</b>
Takeda Oncology	<b>2,609</b>	<b>(2,609)</b>	-
Pfizer	-	<b>23,118</b>	<b>23,118</b>
Novartis Killi Climb	-	<b>8,243</b>	<b>8,243</b>
	<b><u>127,734</u></b>	<b><u>27,037</u></b>	<b><u>154,771</u></b>
<b>TOTAL FUNDS</b>	<b><u>409,720</u></b>	<b><u>(26,916)</u></b>	<b><u>382,804</u></b>

**THE INTERNATIONAL CML FOUNDATION**

**NOTES TO THE FINANCIAL STATEMENTS - continued  
FOR THE YEAR ENDED 31ST AUGUST 2020**

**12. MOVEMENT IN FUNDS - continued**

Net movement in funds, included in the above are as follows:

	Incoming resources £	Resources expended £	Movement in funds £
<b>Unrestricted funds</b>			
General fund	<b>40,064</b>	<b>(97,932)</b>	<b>(57,868)</b>
Cepheid	<b>3,915</b>	-	<b>3,915</b>
	<b>43,979</b>	<b>(97,932)</b>	<b>(53,953)</b>
<b>Restricted funds</b>			
Bristol-Myers Squibb	-	<b>(680)</b>	<b>(680)</b>
Novartis Pharmaceuticals Corporation	-	<b>(1,035)</b>	<b>(1,035)</b>
Takeda Oncology	-	<b>(2,609)</b>	<b>(2,609)</b>
Pfizer	<b>117,458</b>	<b>(94,340)</b>	<b>23,118</b>
Novartis Killi Climb	<b>26,144</b>	<b>(17,901)</b>	<b>8,243</b>
Novartis Colt	<b>4,960</b>	<b>(4,960)</b>	-
Bristol-Myers Squibb	<b>7,830</b>	<b>(7,830)</b>	-
	<b>156,392</b>	<b>(129,355)</b>	<b>27,037</b>
<b>TOTAL FUNDS</b>	<b>200,371</b>	<b>(227,287)</b>	<b>(26,916)</b>

**Comparatives for movement in funds**

	At 1/9/18 £	Net movement in funds £	At 31/8/19 £
<b>Unrestricted funds</b>			
General fund	355,308	(73,322)	281,986
<b>Restricted funds</b>			
Bristol-Myers Squibb	-	680	680
Novartis Pharmaceuticals Corporation	-	124,445	124,445
Takeda Oncology	-	2,609	2,609
	-	127,734	127,734
<b>TOTAL FUNDS</b>	<b>355,308</b>	<b>54,412</b>	<b>409,720</b>

**THE INTERNATIONAL CML FOUNDATION**

**NOTES TO THE FINANCIAL STATEMENTS - continued  
FOR THE YEAR ENDED 31ST AUGUST 2020**

**12. MOVEMENT IN FUNDS - continued**

Comparative net movement in funds, included in the above are as follows:

	Incoming resources £	Resources expended £	Movement in funds £
<b>Unrestricted funds</b>			
General fund	146,022	(219,344)	(73,322)
<b>Restricted funds</b>			
Incyte	31,847	(31,847)	-
Bristol-Myers Squibb	25,277	(24,597)	680
Novartis Pharmaceuticals Corporation	143,312	(18,867)	124,445
Takeda Oncology	31,848	(29,239)	2,609
	<u>232,284</u>	<u>(104,550)</u>	<u>127,734</u>
<b>TOTAL FUNDS</b>	<u>378,306</u>	<u>(323,894)</u>	<u>54,412</u>

A current year 12 months and prior year 12 months combined position is as follows:

	At 1/9/18 £	Net movement in funds £	At 31/8/20 £
<b>Unrestricted funds</b>			
General fund	355,308	(131,190)	224,118
Cepheid	-	3,915	3,915
	<u>355,308</u>	<u>(127,275)</u>	<u>228,033</u>
<b>Restricted funds</b>			
Novartis Pharmaceuticals Corporation	-	123,410	123,410
Pfizer	-	23,118	23,118
Novartis Killi Climb	-	8,243	8,243
	<u>-</u>	<u>154,771</u>	<u>154,771</u>
<b>TOTAL FUNDS</b>	<u>355,308</u>	<u>27,496</u>	<u>382,804</u>

## THE INTERNATIONAL CML FOUNDATION

### NOTES TO THE FINANCIAL STATEMENTS - continued FOR THE YEAR ENDED 31ST AUGUST 2020

#### 12. MOVEMENT IN FUNDS - continued

A current year 12 months and prior year 12 months combined net movement in funds, included in the above are as follows:

	Incoming resources £	Resources expended £	Movement in funds £
<b>Unrestricted funds</b>			
General fund	186,086	(317,276)	(131,190)
Cepheid	3,915	-	3,915
	<u>190,001</u>	<u>(317,276)</u>	<u>(127,275)</u>
<b>Restricted funds</b>			
Incyte	31,847	(31,847)	-
Bristol-Myers Squibb	25,277	(25,277)	-
Novartis Pharmaceuticals Corporation	143,312	(19,902)	123,410
Takeda Oncology	31,848	(31,848)	-
Pfizer	117,458	(94,340)	23,118
Novartis Killi Climb	26,144	(17,901)	8,243
Novartis Colt	4,960	(4,960)	-
Bristol-Myers Squibb	7,830	(7,830)	-
	<u>388,676</u>	<u>(233,905)</u>	<u>154,771</u>
<b>TOTAL FUNDS</b>	<u>578,677</u>	<u>(551,181)</u>	<u>27,496</u>

#### 13. RELATED PARTY DISCLOSURES

There were no related party transactions for the year ended 31st August 2020.